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ABSTRACT
Creation and Use of Software for Analysis of
Kinetic Proteomic Experiments
Bradley C. Naylor
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Proteins are constantly synthesized and destroyed to ensure sufficient functioning
proteins to meet cellular needs, a process called protein turnover. Synthesis and degradation are
carefully balanced over time to ensure that average protein concentrations do not change
drastically. The status quo of the cell, or protein homeostasis, is required for the health of the
organism. If protein homeostasis breaks down, serious diseases, such as Alzheimer’s, can result
when proteins aggregate instead of being degraded properly. Because protein turnover is the
means to maintain protein homeostasis while keeping sufficient functioning proteins, measuring
protein turnover is critical to understanding biological processes and disease states. Measuring
protein turnover rates on a broad scale is possible using a method called kinetic proteomics, and
the improvement of kinetic proteomics is where I have focused the work for this dissertation.
In this dissertation, I will review the history and general strategies for performing kinetic
proteomics. I will then demonstrate that I have published an open source, user-friendly program
for other scientists to use to perform kinetic proteomics data analysis, as well as publishing a
novel discovery of key ribosomal subunits being replaced within the lifetime of the ribosome,
which was discovered through use of kinetic proteomics. Finally, I will discuss work that is
ongoing to improve my software tool for use in human subjects, and work being done to
combine kinetic proteomics with other global analysis methods to make novel biological
discoveries.
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1. Introduction

All biological systems are dynamic. As cells alter gene expression in response to stimuli,
amounts of proteins and signaling molecules change, and old proteins undergo replacement with
new copies to ensure the cell has sufficient working proteins to perform necessary functions.
Loss of the dynamic controls may occur due to deregulation of synthesis or degradation 5,6, and
is thought to be the cause of biological aging as well as diseases such as Alzheimer’s disease,
which is characterized by a lack of protein removal10.
Large (–omics) scale studies following multiple analytes (1000’s) are well suited for
studying complex systems like a cell. –Omics studies attempt to see all of a certain type of a biomolecule in a cell, tissue, or organism. Of particular interest is proteomics, because proteins are
responsible for carrying out most cellular reactions and responses. Altered conditions within the
cell are largely the result of a change in protein expression and behavior. These changing
conditions may result from different disease states, environmental conditions, dietary inputs, and
so on.
Proteomic methods for determining the presence of proteins in samples or measuring
differences in protein quantity between samples are relatively mature and advanced
technologies11-1310. In contrast, kinetic proteomics, which measures how quickly proteins are
turned over, that is destroyed and replaced by new copies, is a more recent method. The
underlying premise is that experimental perturbations to the proteome should also change the
1

turnover rates of proteins, and these kinetic changes may be far more visible than changes in
protein presence or quantity. Kinetic proteomics is also useful in cases where protein quantity
and expression are not changing, but the turnover rate is, such as in liver cirrhosis12,14.
In this dissertation, I will begin by further discussing the significance and practical
applications of kinetic proteomics. I will then discuss the history of kinetic proteomics in order
to describe its foundations and further demonstrate its utility. Next, I will elaborate on the
different ways that kinetic proteomics can be done, in order to illustrate why our lab uses some
kinetic proteomics techniques and not others. Finally, I will outline the contributions I have
made to the field of kinetic proteomics, namely the creation and use of software tools to analyze
kinetic proteomic data.

1.1 Practical Uses of Kinetic Proteomics
The first question to be asked of any method is “what is the benefit of this method?”
Kinetic Proteomics has several advantages over current proteomics methods. The first is that it
is orthogonal to current tests. Because of this it can be combined with various other assays,
including other mass spectrometry methods, and still provide unique information. The
combination of multiple large data sets from many measurement types is an idea that is
becoming more popular in proteomics. The combinations give a more holistic picture of any
biological condition, so causes and effects can be better understood14. The most obvious method
to combine with kinetic proteomics is quantitative proteomics17, since the only way for the pool
size of protein to change is for the ratio of synthesis to degradation (protein turnover rate) to
change. The addition of RNA-Seq to quantify RNA amounts and compare them against the
turnover rate of their protein product has also been used to investigate gene expression19. These
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types of studies provide better understanding of disease and treatment effects, which can benefit
clinical scientists and physicians.
Proteomics relies on mass spectrometry which is very practical in the clinic, where few
samples should be required, and as much data as possible gleaned as rapidly as possible. The
metabolic incorporation of isotopes used for kinetic proteomics methods labels many biomolecules that can be analyzed by mass spectrometry2,20. A few targeted lipid and protein
turnover rates from blood or limited biopsies can reveal information about diseases2,2019, exercise
and cardiac health21, and labeled DNA can be used to measure cancer progression20. Models of
heart disease22, aging23-25, metabolism23-25, skin disease10,26, and drug testing10,26 have all been
investigated using kinetic measurements of various bio-molecules. Some studies of proteins
have been translated to clinical settings already10,26.
A more recent, but related, idea is the virtual biopsy28. A patient is provided with a heavy
isotope tracer to initiate metabolic labeling, and then blood is collected at predetermined time
points. Since blood proteins are produced in a variety of tissues, the turnover rates of proteins in
the circulatory system can be used to extract information about the organs that produced the
proteins without the need for a direct biopsy. This method can be used to measure proteins
directly involved in disease, such as collagen in diseases with liver cirrhosis30,31, or to analyze
protein production in specific tissues to assess overall tissue health21,32-36.
Kinetic proteomics is useful for both clinical and basic research applications, providing
unique information unavailable by other methods. However, the field of kinetic proteomics did
not begin this way, and does have limitations. I will present a review of the history of this
method to demonstrate its applications, its limitations, and how its limitations have been
overcome.
3

1.2 Historical Development of Kinetic proteomics
1.2.1 The Foundation of Dynamic Measurements of Bio-Molecules
The foundation for what would become kinetic proteomics began in the 1930s when Dr.
Rudolf Shoenheimer used stable isotopes to determine that lipids21,32-36 and proteins21,32-36 are
replaced by cells over time. He also demonstrated that two different stable isotopes, 15N and 2H,
could be incorporated into new bio-molecules of an experimental animal. Exact turnover rates
could not be determined because the mass spectrometry technology was not up to the task: the
quantity of an isotope could only be determined in a measurement of the pure element. Complex
mixtures of molecules, such as amino acids and proteins, were beyond the reach of the
technology.
In the 1980’s more progress was made by Dr. Spencer Commerford, who found that both
DNA and proteins incorporate 3H when it was provided to laboratory animals in drinking water.
While the radioactivity of the 3H complicates its use in humans, it enabled the amount of isotope
incorporated into different amino acids in proteins to be determined by the radioactivity they
exhibited. As expected, the essential amino acids exhibited little radioactivity and the nonessential amino acids exhibited more.
1.2.2 Development of Kinetic Proteomics: From Small Molecules to Full-scale Proteomics
In the 1990s mass spectrometers had improved to the point where analyzing stable
isotopes in intact biomolecules was possible. Stable isotope labeling allows many bio-molecules
to have a detectable label without the hazards and instability of radioactive isotopes. Work
began with small bio-molecules, such as lipids and nucleotides. Labeled small bio-molecules
can be used to determine biological conditions, DNA labeling rates are a metric of cell
proliferation rates for example41,42, but the ability to perform protein analysis was still
4

undeveloped. It took several years to apply these techniques to proteins, but in the early 2000s
researchers began to use stable isotopic metabolic labels in proteins. By isolating a specific
protein43,44 or many proteins (with the goal of getting an average rate for all proteins)

23,33,45

,

then digesting them to amino acids and measuring the incorporation of label into one or more
amino acids.
Proteins were more difficult to analyze by mass spectrometry because mass
spectrometers can only analyze molecules in the gas phase. All of the molecules described
above required chemical modification to be able to enter the gas phase. Unlike DNA, proteins
exist in many forms with many different properties. Therefore, important information about
cellular operations can be gained by monitoring individual protein species, but the average
turnover rate less informative. Therefore, a new technology was needed to allow peptides to
enter the gas phase intact, so proteins could be identified without excessive purification. The
new technologies to allow peptides and proteins to enter the gas phase was actually developed in
the 1980’s 46-49. Matrix Assisted Laser Desorption\Ionization (MALDI) allows the ionization of
peptides within a matrix of organic acid, while Electro-Spray Ionization (ESI) allows the
ionization of all peptides in a constant stream of liquid. Both of these methods allow the
peptides to enter the gas phase and be analyzed by mass spectrometry. It took several years to
apply these techniques to kinetic measurements, because while the peptides could be seen in the
mass spectrometer, they could not be identified making analysis of individually separated
proteins of known identity a better choice.
By the late 1990s and 2000s the technology and analysis software had advanced
sufficiently so peptides in a mass spectrometer could be identified and matched to a database of
proteins present in a given organism. With the ability to identify peptides, mass spectrometry
5

could be used to measure the incorporation of stable isotopes into intact peptides. These
experiments used either synthetically labeled amino acids or 2H, which labeled amino acid used
for making proteins in the amounts detailed by Commerford46-49, in the organism’s diet. The
labeled amino acids were incorporated into proteins. Once heavy label was incorporated, the
proteins could be separated by two-dimensional (2-D) electrophoresis, and then analyzed using
MALDI or ESI. While a few labs started targeting specific proteins using these new methods51,
dynamic measurements were still limited. Initially measuring peptide incorporation was only
moderately more convenient than digesting the separated proteins to amino acids. An important
step facilitating kinetic proteomics was made by Doherty et al. in the mid 2000s24,53,54. Instead
of simplifying the analysis to one protein target, Doherty used similar experimental methods to
analyze all observed proteins. The ability to measure isotope incorporation in many proteins at
once paved the way for modern kinetic proteomics to measure thousands of protein turnover
rates in a single experiment. Interestingly, while many of the earlier studies had relied on
theoretical models24,53,54, Doherty used an empirical method. In her experiment, labeled valine
was provided to chickens, and the incorporation of the valine into proteins was measured.
Peptides containing two or three valines were used to determine how much labeled valine was
available, while peptides with a single valine were used to construct kinetic curves and calculate
rates. This strategy worked well and set the stage for more improvements to kinetic proteomics
in the early 2010s.
The first major advancement in the 2010s was the use of 2H for measuring many proteins
at a time. The initial work was done by the Previs lab, who first used deuterium for large scale
kinetic proteomics24,53,54. Hellerstein followed with a more theoretical model for analyzing the
dynamic proteomic data and using kinetic proteomics in humans55,56. Finally, Ping followed
6

within a few years adopting the Previs method initially, but eventually developing an improved
mathematical model of deuterium incorporation in humans57. Because of this progress, any
investigator using kinetic proteomics is faced with a variety of choices about labeling techniques,
calculation methods, and analysis tools. I will analyze these below and provide justification for
the approaches I have chosen in my research.

1.3 Modern Kinetic proteomics
1.3.1 Method for Label Administration
How to administer isotopic labels to experimental subjects is critical for kinetic
proteomics: the isotopic labeling strategy determines analysis methods that can be used, which
amino acids are labeled, which other bio-molecules are labeled, where on the bio-molecules the
label is incorporated, and the software tools available to the researcher. There are two major
heavy isotope labeling strategies used in kinetic proteomics. The first is metabolic labeling, in
which the subject is fed raw material with an added isotopic label. This labeling is commonly
done with 2H2O, because it is non-toxic (even in humans59), easy to use, and will label all biomolecules in the body that are synthesized with hydrogen50,60. Other commonly used materials
are nitrogen(15N)-containing salts50,6027 and H218O 52,61. The cell then uses the labeled molecules
to create monomers, such as amino acids, incorporating the provided isotopic label into the
desired polymer, such as protein.
The second strategy, Stable Isotope Labeling of Amino acids in Mammals (SILAM), is
based on providing the labeled amino acids and skipping some of the metabolic steps52,61. While
SILAM was originally intended for measuring quantities of protein, the adaptation of the method
for kinetic proteomics is relatively simple. In this method, a heavy-labeled essential amino acid
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is provided to the subject; usually this is leucine23,62, although other amino acids23 or even all
amino acids64 are possible choices. The labeled amino acid(s) are incorporated into new
proteins. Advantages and disadvantages of these two methods are described in Table 1-1.
Table 1-1: Comparison of Advantages and Disadvantages of Metabolic Labeling and SILAM Style

Labeling

Metabolic Labeling

Advantages

SILAM Style Labeling

Disadvantages

Pros

Cons

Easy to use in
humans23,58,65

Label incorporation
can shift based on
metabolic
conditions23,58,65

Very useful in cell
culture66

Large amounts of
extra amino acids in
the diet can disrupt
metabolism27,59,67,68

Most peptide
populations contain a
labeled amino
acid27,59,67,6866

Software is currently
more limited than the
SILAM method59

Software tools widely
available that will
perform calculation
with minimal inhouse work55,65,69

Only peptide
fragments that
contain the labeled
amino acid(s) are
useful for turnover
calculations59,61

2

Difficult to rapidly
achieve stable isotope
enrichments in
humans16,59,61

Mass spectra of
labeled and unlabeled
species are easily
distinguishable65

Enrichment of amino
acid pool is difficult
to determine without
intravenous infusion
or control of the
entire diet55,7065

H enrichment in
body water is easily
determined59,6158

2
All molecules
H can cause vertigo
biosynthesized using in larger doses68,7161
the heavy element are
labeled68,71

Calculation is
conceptually easy to
understand

Stable isotope
enrichment causes
rapid saturation of
every cell with
labeled amino
acids23,52,56,65

Dietary amino acids
require variable
amounts of time to
enter the amino acid
precursor pool,
complicating
calculations23,52,56,65
8

In the table above, there are two points that deserve expansion. The first is the software
requirement. Many commercial or freeware proteomics tools, such as PEAKs and Skyline, have
been developed for the common quantitative techniques SILAM and its cell culture analogue
SILAC. These methods generally rely on mixing samples both with and without a heavy
isotope, and then comparing the signal abundance ratios of the distinctly separated mass spectra.
In kinetic proteomics the analysis is similar: samples are analyzed, and the ratio of heavy to light
(new to old) molecules can be compared over a time course. Since SILAM analysis software
performs this comparison readily, mass spectrometry groups already have access to software to
do this form of analysis, and simply have to the combine the results from all experimental timepoints to determine a kinetic curve. Metabolic 2H labeling uses a lower amount isotopic
enrichment than SILAM style labeling, for reasons of both cost and safety73,74. As a result, the
change in molecular weight is not as large as that which SILAM/SILAC software expects. In
fact, peptides labeled by low enrichment 2H can be misidentified by the software as contaminants
due to unnaturally distributed isotope patterns.
Despite the computational difficulty, metabolic labeling with 2H has a key advantage.
The labeled amino acids used in the SILAM method need to make it through the gut and various
other metabolic processes. They must be transported to each cell before they are attached to
tRNAs and incorporated into a protein. This creates differences in availability for different
organs and different locations in each organ. Measuring the progress of amino acid availability
is also difficult because the amount of labeled amino acids in the blood is not necessarily
indicative of the labeled amino acids in the cell52,58,75. The resulting incorporation speed is no
longer negligible, and the turnover rates must now be modeled as two pools: one of amino acids
in the diet, and the other attached to the tRNA molecules52,58,7558. The necessity of this two-pool
9

model complicates kinetic calculations significantly. The distribution of 2H to each cell from
drinking water or injection is much faster. The 2H equilibrates rapidly and uniformly through the
organism through hydrogen exchange. While there is a delay resulting from synthesis of the
amino acids and loading the tRNA13,38,73, it is more uniform and generally negligible except in
very fast experiments13,38,73.
Therefore, for my work we chose metabolic 2H2O labeling. Calculation with this method
was simplified by the lack of a significant incorporation time compared to the length of the
experiment13,38,73. Software for analysis of this type of data is less well known than software for
SILAM experiments, so we created our own specialized software tools, which would in turn aid
other researchers.
1.3.2 Measuring Label Incorporation or Decay
After a label for the kinetic proteomics experiment has been chosen, the researcher must
determine if the label should be measured as it is being incorporated or as it is being removed.
Label decay methods are analogous to classic pulse-chase experiments13,14,76. The label is
applied until all the proteins of interest have incorporated enough of the label that the labeled
population is easily observed as distinct from the unlabeled population. The labeling source,
either labeled food or water, is removed and the amount of label in proteins is measured at
various times. The amount of label present at the various times are fit to an experimental decay
curve as the labeled population decreases, and a turnover rate calculated.
An alternative approach is to model label incorporation, and starts the experimental
subjects with no extra heavy isotopes24,45,53. The isotopic label is applied at the start of the
experiment and measurement of incorporation into the bio-molecules of interest begins
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immediately. The data points from various time-points are fit to an exponential rise-to-plateau
equation for calculation of a rate constant.
The advantage of using decay modeling is that the amount of signal early in the
experiment is much higher. Since the data is fit to an exponential model in both methods the
early measurements, where the plateau has not been reached, are more important in determining
the fit line. Decay has more signal at these points, and thus has better signal to noise on the most
critical points. However, we chose the incorporation method of labeling for my experiments and
software development. This focus on label incorporation measurements was largely due to
practicality; it is easily applicable to a proteome scale experiments where turnover rates vary by
more than four orders of magnitude, while attempting to pre-label while ensuring significant
labeling of proteins across a wide range of kinetic ranges is time-consuming and expensive35,36.
Knowing the absolute endpoints possible for isotopic enrichment of every protein regardless of
rate simplifies the modeling and allows analytical validation of the experimental isotope
enrichment. The incorporation labeling method also provides confidence when observing
potentially important biological deviations35,36 from a theoretical model.
1.3.3 Theoretical vs Empirical Models
Once the metabolic labeling experiment has been performed and the isotope data
extracted from the mass spectral files, the data must be analyzed. Both theoretical and empirical
methods have been used to turn peptide isotopic data from a 2H incorporation experiment into a
functional kinetic curve from which a turnover rate can be determined.
The empirical method is conceptually straightforward. During the experiment, a steady
amount of heavy isotope label is applied, and the change in the isotope pattern of target
molecules at several time points is measured23,24 (Figure 1-1). At each time-point the neutromer
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peaks within the isotope pattern are weighted (normalized peak abundance multiplied by the
number of extra neutrons in the peak) and summed together. The weighted sum of an isotope
pattern with no heavy label added is subtracted from the weighted sums at all time-points. The
data from all time points are fit to a first order rate curve to determine the turnover rate constant
(Figure 1-1). This method requires that the experiment extend to sufficient times to describe
each saturation curve.
The theoretical method, although more computationally intensive, removes this
requirement for very long labeling times. The concept was first formalized in an approach called
Mass Isotopomer Distribution Analysis (MIDA)45. MIDA is based on the principle that an
isotopically diverse population of any molecule is detected by a mass spectrometer. For example,
Figure 1A represents the natural distribution observed for a single peptide GAFGKPQGTVAR.
Because isotopes of carbon, hydrogen, oxygen and other elements within the peptide were
present at the time of synthesis, they were incorporated at a percentage representative of the
availability. The relative intensities of the different m/z values in the molecular population are
the result of the different isotope availabilities. MIDA assumes no bias exists for, or against,
heavy isotopes during the creation of bio-molecules. These principles allow the use of
combinatorial statistics to determine the theoretical isotope pattern without experimental
measurement of the isotopic pattern before or at the endpoint of increased heavy label
availability (Figure 1-1 D-E). After introducing the 2H, mass spectra of the peptide can be
collected to determine the amount of labeled protein at the time the data was collected. Although
a single measurement allows fitting a first order rate curve (Figure 1-1 F) and determination of a
turnover rate constant, combining the data from multiple time points improves signal to noise
and fitting confidence.
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Figure 1-1 Theoretical vs Empirical Analysis Method: The difference between Empirical (B, C) and

Theoretical (D, E, F) calculations using the peptide GAFGKPQGTVAR measured at charge state 2 as
an example. The isotopic envelope of the peptide as detected by the mass spectrometer is shown in panel
A (no extra heavy isotopes are present). The m/z values on the x-axis represent the mass to charge
ratios for the sequence with different numbers of extra neutrons (0-3 extra going from left to right). In
the empirical method, a weighted sum of the intensities of the peaks (intensity multiplied by the number
of extra neutrons) is calculated from the black bars representing experimental endpoint measurements
(Panel B). The weighted sums of the baseline intensity (blue lines) are then subtracted from the
measured weighted sum (Panel B). In Panel C the weighted sums are plotted at multiple times (red dots)
and a curve fit to the points (black line) which can be used to determine the turnover rate. In the more
complex theoretical approach, the maximum possible change of each peak in panel A at different
enrichments is calculated by combinatorial statistics (Panel D); M(number) indicates the change in the
peak with (number) extra neutrons. The experimental amount of enrichment is selected (red dots). In
Panel E, actual measurements at a time point (black bars) are compared with the intensities at baseline
(blue lines) and the predicted change at maximum label incorporation (red lines). The difference
between the experimental change (blue to black) divided by maximum theoretical change (blue to red)
for each peak can be expressed as a percent. In Panel F measurements at several times are plotted in
red. The black line is fit to the data, and the turnover rate determined from the equation of the curve.
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Table 1-2: Comparison of Advantages and Disadvantages of Theoretical vs. Empirical calculation
models

Theoretical
Advantages

Empirical

Disadvantages

Advantages

Disadvantages

Easy to adjust to
non-constant label;
necessary for human
labeling24,4545

Need to know the
Knowledge of
number of sites
monomer enrichment
available for stable not required77
2
H incorporation for
every amino acid

Requires very strict
data filtering51

Can detect cases
where labeling is
incomplete35,5151

Susceptible to
instrument bias

Cannot detect
instances where the
entire pool of
proteins does not
turnover23,24,50

Can use each peptide
isotope pattern to
calculate
measurement
error23,24,5023

Conceptually easier
to understand.

If using the same
instrument for all
measurements,
resistant to
instrument bias

The theoretical
changes in isotopic
incorporation can be
used to calculate
enrichment23,24,50

For my work, we chose the theoretical method. It was attractive due to the ability to deal
with a changing amount of label in the subject, and enabled filtering based on theoretical
differences. The flexibility to deal with a changing amount of label deserves elaboration. If the
amount of heavy isotope in the experimental subject changes over time, as is often the case when
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working with humans68, the heavy isotope incorporation will not be uniform over the time course
of the experiment. As a result, the spectral changes due to the maximum isotope incorporation
(red lines, Figure 1-1 E) at any point will not be stable. Not only will it vary by the amount of
heavy isotope the experimental subject has consumed thus far, but it will be different for every
protein depending on the turnover rate of that protein: the longer it takes for a protein to be
replaced (turned over), the wider the variety in amounts of deuterium present in the amino acids
of that protein’s population. This makes applying a uniform correcting factor to all proteins
unfeasible. Instead, any correction needs to be applied on a protein-by-protein basis80. The
protein-by-protein correction requires mathematical modeling which cannot be applied to the
empirical method, where it is necessary to assume a constant maximum label availability. The
application of theoretical modeling requires software to perform individual calculations for each
peptide on a proteomic scale, which is commonly 60,000 peptides at 8 time points. We will
discuss these tools in the next section.
1.3.4 Software
Specialized software is utilized in every step of mass spectrometry based proteomics
experiments. The amount of data generated in any experiment is simply too large and complex
to fully analyze by hand. For example, SearchGUI50 is a program that determines the identity of
peptides from mass spectrometry data by accessing up to 10 different identification algorithms,
each from a different research group. Several data analysis and visualization tools exist such as
Skyline45 and PeptideShaker82 to provide statistics for identified spectra. In order to enable
different programs to analyze the same data, a file format converter such as MSConvert24 is
required.
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The open availability of trusted software tools such as these saves programmers from
having to create software that replicates the work of others. Earlier programs can perform the
basic tasks of proteomic analysis, allowing users to convert files to an appropriate file type, and
provides them the choice of which search engine and analysis tool they prefer to use to perform
peptide identifications. The programmer is then free to focus on creating entirely new software
tools, which is beneficial for kinetic proteomics because the calculation process can be quite
involved.
Several groups have already provided software to facilitate the calculations needed for
the complex calculations in kinetic proteomics. Topograph1, for example, is a program based on
the SILAM style calculations used in the Doherty experiments2. A different program developed
by the Sandygov lab uses metabolic labeling with 2H based on the empirical calculations detailed
in Figure 1-1 panels B-C-3,4. Both of these calculation types are valid, but they do not
incorporate theoretical analysis of 2H labeling. This leaves a rather large gap in software options
because, as explained above, theoretical calculations are the best way to perform dynamic
proteomic experiments in humans. In our software3,4, I have sought to fill this gap as well as
improve on what these other packages provide to allow researchers greater flexibility in their
experimental methods.
There is a previous software package that can perform calculations for theoretical
labeling with 2H, even in humans, called ProTurn5,6. However, ProTurn is not openly available
and is limited by only examining one portion of an isotope pattern, while DeuteRater uses the
abundance of multiple isotopic peaks and the spacing between them to quantify the accuracy of
its measurements. This is detailed in the “DeuteRater: a Tool for Quantifying Peptide Isotope
Precision and Kinetic Proteomics” Chapter. While the initial release of DeuteRater cannot
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perform calculations on human subjects, I am working to incorporate the use of changing isotope
enrichment profiles. Improvements to DeuteRater for human work are detailed in the chapter
“Creation of Software Tools and Methods for Measurement of Kinetic Proteomics in Humans”.
In addition, DeuteRater is freely available for all to use and modify, while ProTurn requires
specific permission of its creators to access. Further, DeuteRater provides options for labeling
different biological systems with different isotopic labels. My work provides an open source
improvement that accesses more of the information available in the isotope labeling experiments.

1.4 Conclusion and My Contribution
Although initially viewed as a niche application, kinetic proteomics has developed into a
practical proteomics method. As methods of kinetic proteomics have improved, the approach
has become a feasible way to answer many biological questions. The technique yields unique
biological information, either through analysis of protein turnover rates on their own, or by
combination with other –omics techniques. Experiments can also be performed using a wide
variety of isotopic labels and calculation methods in diverse biological systems.
However, one of the major limitations to performing kinetic proteomics experiments is
the current lack of user-friendly openly available software tools to perform the calculations. The
focus of my work has been to provide such software. DeuteRater also improves on the kinetic
proteomics software currently available to researchers, and will help other scientists add kinetic
proteomics capability to their labs. This dissertation details the software development for kinetic
proteomics experiments involving small animals in the “DeuteRater: a Tool for Quantifying
Peptide Isotope Precision and Kinetic Proteomics” chapter and humans in the “Creation of
Software Tools and Methods for Measurement of Kinetic Proteomics in Humans” chapter. The
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utility of the software and kinetic proteomics on its own is demonstrated in “Mechanisms of in
vivo Ribosome Maintenance Change in Response to Nutrient Signals” and in conjunction with
other –omics techniques in “Short-Term Calorie Restriction Elicits Nutrient-Specific PostTranscriptional Regulation of Proteostasis”.
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2. DeuteRater: a Tool for Quantifying Peptide Isotope Precision and Kinetic Proteomics

2.1 Chapter Summary
This chapter is the accepted manuscript introducing our DeuteRater kinetic proteomics
analysis program, which was published in early 2017. The manuscript has been edited for
formatting, minor error corrections, and to reflect the fact that the article has been published.
This paper was published in Issue 10 of Bioinformatics doi:10.1093/bioinformatics/btx009.
2.1.1 Authors in Order of Contribution
Bradley C. Naylor, Michael T. Porter, Elise Wilson, Adam Herring, Spencer Lofthouse,
Austin Hannemann, Stephen R. Piccolo, Alan L. Rockwood and John C. Price
2.1.2 Contributions of Major Authors
I performed most of the programming and was the person primarily responsible for the
care of the experimental animals analyzed in this paper. The most significant contribution by
another author was made by second author Michael Porter who wrote the extractor module,
tested it, and prepared the samples for analysis.

2.2 Abstract
2.2.1 Motivation
Using mass spectrometry to measure the concentration and turnover of the individual
proteins in a proteome enables the calculation of individual synthesis and degradation rates for
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each protein. Software to analyze concentration is readily available, but software to analyze
turnover is lacking. Data analysis workflows typically do not access the full breadth of information
about instrument precision and accuracy that is present in each peptide isotopic envelope
measurement. This method utilizes both isotope distribution and changes in neutromer spacing,
which benefits the analysis of both concentration and turnover.
2.2.2 Results
We have developed a data analysis tool, DeuteRater, to measure protein turnover from
metabolic D2O labeling. DeuteRater uses theoretical predictions for label-dependent change in
isotope abundance and inter-peak (neutromer) spacing within the isotope envelope to calculate
protein turnover rate. We have also used these metrics to evaluate the accuracy and precision of
peptide measurements, and thereby determined the optimal data acquisition parameters of different
instruments, as well as the effect of data processing steps. We show that these combined
measurements can be used to remove noise and increase confidence in the protein turnover
measurement for each protein.
2.2.3 Availability
Source code and ReadMe for Python 2 and 3 versions of DeuteRater are available at
https://github.com/JC-Price/DeuteRater.

Data is at https://chorusproject.org/pages/index.html

project number 1147. Software has only been tested on Windows machines. Supplemental
materials are available at Bioinformatics online.

2.3 Introduction
Cells are dynamic, with synthesis and degradation of the cellular machinery occurring
constantly throughout the life of each cell. Protein homeostasis (proteostasis) is achieved by a

26

careful balance of synthesis and degradation rates resulting in stable concentrations. Measuring
protein concentrations over time does not characterize the changes in synthesis and degradation
that occur as the cell works to maintain proteostasis. Measurement of protein turnover is
required to capture this information.
Mass spectrometry can measure both protein concentration and turnover in the same
sample5,6. Methods for measuring in vivo protein concentrations (quantitation) are welldeveloped7,8. Metabolic labeling with stable isotopes and mass spectrometry has been used for
many years to monitor in vivo dynamics1,3,4,9-12. Only recently has it become possible to monitor
individual in vivo protein turnover rates within complex samples. This can be done by either
providing labeled amino acids1,4,10,12 or through in situ labeling of nonessential amino acids.
Both approaches result in permanently labeled proteins, so turnover and concentration can be
measured simultaneously within complex mixtures using mass spectrometry. Metabolic labeling
with deuterated water (D2O) has several experimental advantages (Supplemental Table 2-S1),
but the calculations represent a challenge for proteome scale analysis. To facilitate this analysis,
we have developed DeuteRater, a user-friendly tool to quantify data accuracy and precision using
previously established combinatorial statistics16.
In order to discuss our data analysis, we will use the vocabulary proposed by Smith and
coworkers18. Each heavy neutromer (M1, M2, etc.) within the pattern has a highly predictable
relative intensity (Ix) and distance (Sx) from the monoisotopic neutromer (M0, Figure 2-1). The
ratio of naturally occurring heavy isotopes create a predictable distribution of heavy neutromers.
Interestingly, the exact mass of the neutromer is slightly different depending on which element
holds the extra neutron. The observed mass of a neutron changes, because some mass is
converted to energy to supply the necessary strong nuclear force. Larger nuclei require more
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force so the carbon neutromer is lighter than the deuterium. This creates a series of
isoneutromers within each neutromer (fine structure peaks with different heavy elements, 13C, D,
etc., Figure 2-1 A inset). The combination of Ix and Sx has been used to differentiate between
distinct elemental combinations, allowing discrimination between classes of molecules based on
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Figure 2-1 Deuterium labeling causes predictable shifts in the isotope pattern: Each molecule’s
isotope pattern has a series of neutromers (M0, M1, etc.) defined by the number of heavy isotopes.
The position (m/z) and height of the neutromer is defined by the major isotope, 13C (black line inset to
A). Metabolic deuterium labeling changes the major isotope to deuterium (red line inset to A) leading
to a measureable change in both neutromer intensity (ΔIx) and spacing (ΔSx) for each heavy neutromer
peak (red spectrum B). The theoretical changes can be predicted at any molar percent excess (MPE) of
added deuterium (C and D). Data and simulation for peptide LSQTFPNADFAEITK, charge state +2.
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ambient isotopic ratios10. During metabolic deuterium labeling, we shift the major contributing
isoneutromer within each neutromer of the isotopic envelope from 13C to D (Figure 2-1 A inset).
The change in Ix (ΔIx) and Sx (ΔSx) are unique depending on the number of deuterium’s present,
and can be predicted based on the peptide sequence and the deuterium enrichment (Figure 2-1 C
and D). Therefore, during a metabolic labeling experiment, each peptide’s mass spectral pattern
will have multiple distinct and predictable, deuterium-dependent changes for each charge state.
The ratio of time dependent experimental change for each Ix and Sx to the theoretical
maximum reports the fraction of new peptide for each detected ion in each sample. Since the
fraction new ratio should be identical for each ΔIx and ΔSx in a given peptide, any deviation must
come from instrumental or analysis related error. This means that each mass spectrum of a
molecule has 2n-1 semi-independent metrics of turnover (n = number of neutromers observed for
that molecule), which can be combined to analyze instrumental noise and software mistakes as
well as provide turnover rates of proteins. We show here that the both ΔIx and ΔSx are
experimentally useful for measurement of turnover, and that ΔSx is more sensitive to noise.

2.4 Methods
2.4.1 Sample Preparation and Data Collection
For the current experiment, blood samples were collected at different time points after
introduction of the metabolic label (0.4, 1, 2, 4, 8, 16, and 32 days after D2O introduction), and
analyzed by mass spectrometry. Details of animal care, sample preparation, and mass
spectrometry are in the Supplemental Methods along with a graphical representation (Figure 2S1)
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2.4.2 Peptide database assembly
The open source analysis tools PeptideShaker2 and Search GUI1 were used for analysis of
MS/MS fragmentation data as detailed in the Supplemental Methods. Peptide shaker does not
utilize the FDR notation but scores every observed peptide. Peptides with a score greater than 1
based on multiple search algorithms were used for further analysis. The MS/MS fragmentation
data from the unlabeled sample acquisitions were used to assemble a peptide mass and retention
time database for identification of isotopic envelopes in metabolically labeled samples using
DeuteRater (Figure 2-2). The DeuteRater workflow is outlined in the results (Results
“DeuteRater Workflow”).
2.4.3 Accuracy and Precision
In unlabeled samples, we assess accuracy relative to the unlabeled theoretical spectrum.
Normalizing deviation from theory in these unlabeled samples, to the theoretical ΔSx, ΔIx at the
same molar percent excess (MPE) deuterium of the labeled samples, allows us to quantify the
deviation on an experimentally meaningful scale15. Accuracy is calculated using deviation from
theory for the unlabeled peptide (Figures 2-S3, 2-S4, 2-S5 A-C) normalized to the experimental
MPE. In this study, accuracy is only reported for unlabeled samples.
Precision—how well each of the measurements (Figure 2-1 B, ΔSx, ΔIx) agree with each
other—can be measured in both unlabeled and labeled samples. We quantify precision by
calculating the standard deviation between the fraction new peptide reported by each of the ΔIx
and ΔSx measurements available for the individual peptide charge state. The precision is a
measurement of the standard deviation between the neutromers in any isotopic distribution
(Figure 2-S5 D-E). This is determined using the fraction new calculated at experimental MPE
(defined by the user in Results, “DeuteRater Workflow”, “Labeling Table”) and is equally valid
30

for labeled and unlabeled samples. All data represent direct sequence-specific comparisons
except Figure 2-S3.

A

B

Figure 2-2 DeuteRater Workflow: DeuteRater analysis requires MS1 data where the retention time
and sequences of peptides have already been established. Four sequential modules (Panel A) are
presented in the graphical user interface (Panel B) of DeuteRater to conduct the analysis.

2.4.4 Comparison of Rates
We compared the results of this analysis against two published studies (Price et al 2010
and Lam et al 2014) which measured turnover of blood plasma proteins in a similar mouse
model. The Price data was collected using dietary labeled amino acids while the Lam et al data
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was measured using D2O similar to this study. Analyses comparing rates between studies only
considered proteins with rates between 0 and 1 day-1 (Figures 2-4, and 2-S6), because the time
points in this experiment do not adequately constrain rates faster than 1 day-1. In addition,
accession numbers in the published studies often differed due to homology between proteins in
the proteomic databases. To correct this, peptide sequences were matched between current and
published data and the accession numbers from the current SwissProt database. The Price data14
was refit with a median of relevant lag (t0) and protein with a rate fitting coefficient of variance
(CV) of less than 0.2 were used for comparison. For the Lam et al data proteins were limited to
those below one median absolute deviation for the rate (as defined by the authors4,7,12,19). This
selected the highest confidence data from each study in order to ensure noise from different
instruments did not obscure the correlations. For Figure 2-4, to prevent obvious outliers from
influencing our regression analysis we used a Passing-Bablok non-parametric regression (PSIPlot statistical package). Because we used non-parametric statistics, we report the Spearman
non-parametric correlation co-efficient (JMP 12 statistical package).

2.5 Results
2.5.1 DeuteRater Workflow
The DeuteRater workflow has four modules (Figure 2-2); a comprehensive instruction
manual (ReadMe) and a table of applicable filters (Table 2-S2) are provided as supplemental
information.
2.5.1.1 Isotope Extraction Module
The database of peptide mass and retention time (Methods “Peptide database assembly”)
was used to guide extraction of MS1 data (Figure 2-2). To identify peptide isotopic
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envelopes4,7,12,19 within the MS1 spectra, the m/z values (±30 ppm) for M0-M4 of each charge
state (1+ to 5+) for each observed peptide were calculated. DeuteRater then searched for these
m/z values within a retention time window (±1.5 minutes) bracketing the time the peptide was
fragmented and identified in the MSMS spectrum. The elution chromatogram for each isotope
pattern was identified by comparing an m/z and abundance vector for each scan against the
neighboring scans. We utilized the vector based comparison because it was robust and flexible,
allowing simultaneous comparison of changes in m/z and intensity for all neutromers. When the
vector angle changed less than log10 (1.2), the scan was assumed to belong to the peptide
chromatogram. This vector angle criterion agreed well with our visual evaluations of the
chromatogram boundaries for selected peptides.
All scans within the chromatogram were used to calculate a summed intensity and
median neutromer m/z value. For each neutromer all m/z values are analyzed and the outliers
removed by a Median Absolute Deviation test. The median m/z, and summed intensity of each
neutromer in each peptide charge state were then annotated to that entry of a new peptide
database. Ions with an incomplete neutromer series (complete series is four if the neutral mass is
less than 2400 atomic mass units, or 5 if greater than that limit) were removed from the database
prior to the data processing workflow. Theoretically, an incomplete neutromer series would also
yield useful data, but the confidence in correctly assigning the peptide identity for the isotopic
envelope is lower and the subsequent precision analysis would not be comparable. Therefore,
these peptides were removed.
2.5.1.2 Labeling Table
The user enters sample specific labeling time and experimentally determined isotope
enrichments.
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2.5.1.3 Isotope Distribution Calculator
DeuteRater calculates the theoretical deuterium dependent change in the isotope
distribution for each peptide using the EMass algorithm. To accomplish this, the elemental
composition of each peptide is calculated, and the number of stable deuterium sites (X) is
calculated based on the amino acid sequence. The number of isotopic labeling sites in each
amino acid has been shown to be stable in mice and humans. Although DeuteRater allows the
user to define the number of labels, the presets are an average of the literature values specific for
mammalian tissue or cell culture.
The EMass algorithm can be used in two ways. The first method calculates ΔIx and ΔSx
for each peptide at the user defined deuterium enrichment. This method is relatively fast, but
requires recalculation if deuterium enrichment values need to be changed. Alternatively,
DeuteRater can calculate the change in the isotopic envelope at multiple increments between 0
and a user defined limit. The trends in ΔIx, and ΔSx for each neutromer within the pattern are fit
via least squares regression (Figure 2-1 C and D). Regression coefficients for each peptide,
along with R2 and error values for the fits, are then appended to the mass and retention time
database to allow predictions of ΔIx, and ΔSx at any deuterium molar percent excess (MPE) up to
a user defined maximum. This provides flexibility to quickly test the effect of different
deuterium enrichments on data precision, at the cost of longer initial calculation time.
To calculate ΔIx, the individual Ix of both the theoretical and experimental isotope
patterns are normalized to the sum signal intensity of the neutromers (I0 to I3) in the pattern as
previously described4,20. The M4 neutromer, with its corresponding ΔIx and ΔSx is only included
for peptides larger than 2400 Daltons. The normalization of Ix ensures that the theoretical
calculations and experimental measurements are comparable. The Sx is normalized internally
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against the measured monoisotopic peak (M0, Figure 2-1 B). The experimental ΔIx and ΔSx are
calculated versus the unlabeled theoretical baseline. Similarly, maximum theoretical deuterium
dependent changes (ΔIxmax, ΔSxmax) are calculated by subtracting the theoretical unlabeled
spectra from the theoretical spectra at the experimental deuterium enrichment (Figure 2-1 C and
D, dotted line). The experimental changes are then divided by the theoretical maximum change
at the experimentally determined deuterium enrichment (ΔIx/ΔIxmax, ΔSx/ΔSxmax) to calculate the
time dependent ratio of change (fraction new). In an ideal spectrum, the fraction new peptide
calculated for each ΔIx and ΔSx will be the same: deviation from this ratio between the various
ΔIx and ΔSx measurements is a metric of the noise for that individual peptide charge state. The
reported fraction new peptide can be calculated from ΔIx or ΔSx separately or combined into one
metric. Because there are at least 7 measurements available for each peptide charge state (9 for
m/z above 2400), we can apply a median absolute standard deviation correction to combined
calculations to remove outliers and increase the precision. In this analysis, we observed that the
ΔSx measurements often deviated more from the median and were more sensitive to noise.
2.5.1.4 Rate Calculation Module
The user designates whether rates are calculated from ΔSx, ΔIx or combined data. This
choice should be based on the accuracy and precision observed with an instrument (see Methods,
“Comparison of Rates”). For example, we found that ΔIx was usually best for QToF data,
whereas combining ΔSx, and ΔIx provided improved precision with Orbitrap data. If the standard
deviation of the body of measurements for each peptide were below the user defined value (0.1),
the fraction new and the sample time point included in the turnover rate (k) calculation. The
peptide fraction new measurements are fit versus time using the relationship fraction new=a-ae(kt),

where t is time as previously described21-23. Each charge state for each peptide can
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considered a separate point in the fit, or all the data points can be rolled up to a median value
(Table S2). For the data presented in this paper, the asymptote value “a” in the equation was
fixed at one. Currently, the turnover rate calculation assumes a single biological pool of
unchanging concentration using each of the peptides as a replicate measure to calculate the rate
constant. Protein turnover was only calculated when data at three or more (a user defined filter)
time points passed the quality filters.
2.5.2 Accuracy of the isotope distribution varies with instrument data acquisition parameters
This study used three different instruments with multiple m/z resolutions, resulting in
nine data sets. The number of peptide sequences identified and the identity of the sequences
were significantly different between all nine data sets (Figure 2-S2). All detected peptides were
compared for accuracy and precision (Figure 2-S3). Among the instrument configurations
tested, we found that the Agilent 6530 QToF 10,000 m/z resolution (10k1 or 10k2) was generally
the most accurate for ΔIx measurements, but had the least accurate ΔSx measurements. Relative
to the QToF, the Orbitrap Fusion 60,000 m/z resolution (60kf) produced less accurate and
precise ΔIx measurements, but the accuracy of the ΔSx measurements was much higher. This
result was expected because the QToF has been shown to be more accurate for neutromer
intensities1 but the higher mass resolution of the Orbitrap should provide more accurate ΔSx data.
For sequence-specific comparisons, the QToF at 10k and the Fusion at 60k were the best
for ΔI (Figure 2-S5).

Although the QToF collected high quality data on more total peptides

(Figure 2-S3), comparison of matched peptide sequences between the QToF 10k and the Fusion
60k, revealed that accuracy (Figure 2-S5 A-C) and precision (Figure 2-S5 D-F) were comparable
for the ΔI. Although the Fusion at 120k had the most accurate ΔS measurements, the loss of
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accuracy in ΔI outweighed that gain. We observed that the lower resolution acquisition
parameters were better for accuracy and precision in both the XL and the fusion.
2.5.3 ΔSx is more sensitive to noise than ΔIx
We observed that higher m/z resolutions do not necessarily increase ΔSx accuracy. For
example, the 120k Fusion data had the highest ΔSx accuracy and precision among the tested
instruments and parameters (Figure 2-S3). Although we collected data at 240k and 480k
resolution, the increased m/z resolution reduced both the ΔSx and ΔIx accuracy and precision.
This may be due to the slow scan rate for the high resolution experiments. Fewer total
measurements for each peptide chromatogram would increase noise and reduce the confidence
for the peptide. Noisier peptide measurements are filtered out of the data set prior to further
processing, resulting in fewer usable peptide measurements for the kinetics calculations (Results,
“Precision Metrics can Identify Outliers to Improve Kinetic Calculations”).

Longer

chromatographic times could potentially offset this effect. Although the ΔSx is more susceptible
to noise than ΔIx, we observed increased accuracy and precision for combined (ΔIx, ΔSx) from
the 60k data (Figure 2-S3 C, F).
2.5.4 Precision Metrics can Identify Outliers to Improve Kinetic Calculations
When we compared the peptides associated with individual proteins, we observed that the
low precision peptides were often outliers when compared to the entire body of data (Figure 2-3).
In Figure 2-3 A, there are a series of points near the x-axis (open circles) which seem to form a
separate curve.

Increasing the stringency of the precision filter in Figures 2-3 B-C removes the

points. Closer inspection showed that these points were all assigned to the same peptide,
suggesting a possible mistaken sequence. However, extreme precision requirements will also
reduce the number of measurements (Figure 2-3 D-F). This parameter is modifiable in
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DeuteRater, and for all subsequent analyses in this paper, the precision filter was set to require a
deviation less than 0.1.
Turnover rates can be calculated using ΔI, ΔS, or the combination. Typically, ΔS derived
rates were lower confidence, but when multiple high precision peptides were used ΔI, ΔS, and
the combination provided highly consistent values (Figure 2-S6). Interestingly, although the
QToF 10k data had the lowest precision for ΔS overall, we found that when multiple high
precision peptides were used, the resulting turnover rates for these data were almost identical
(Figure 2-S6, closest to 1 on the y axis).

Figure 2-3 Neutromer precision provides information for outlier removal: Extracted peptide isotope
patterns are subjected to a user controlled precision filter prior to calculating the turnover rate.
Requiring increased precision (smaller deviation) preferentially removes results that are outside of the
expected range of rates. By increasing the required precision, we remove more outliers. However
some proteins, like P13020, may lose enough points that the kinetic curve is no longer well
constrained. Therefore the precision filter was set at 0.1 deviation for all analyses presented here.
Circles represent individual peptide charge state measurements; open circles in A are all assigned to
the same peptide suggesting that it was an incorrectly identified sequence.
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2.5.5 Kinetic rates are highly reproducible between studies
We tested technical variability in the turnover measurement by running two identical
sample sets on the QToF at 10k and analyzing the data (Figure 2-4 A and 2-S3, 10k1 versus
10k2). Of the 53 proteins with high quality identifications, the stringent filtering criteria
described above resulted in 27 proteins observed in both studies (Figure 2-4 A). This confirmed
that DeuteRater analysis is consistent. We then compared our rates to published data from an
independent deuterium labeling study of similar design by Lam et al.12 (Figure 2-4 B). There
were 25 proteins observed in both studies with high quality fits, evaluated as described in the
A.

B.

C.

Figure 2-4 Protein turnover rates are highly reproducible between studies: Comparison of technical

replicates highlights the small technical variability between analyses (A). Comparison of turnover rates
in this study against similar deuterium labeling experiment by Lam et al. 1-4 (B) and dietary heavy amino
acids labeling by Price et al.5,6 show strong linear trends (C). Spearman correlation coefficients are
.9777 for (A), .8962 for (B), and .8500 for (C). The unity lines represent absolute agreement between
studies. All data calculated using ΔI.

methods (Methods “Comparison of Rates”). Passing-Bablok regression analysis reported that
there was a strong linear correlation up to ~0.5 Day-1, suggesting that the biological sampling
rate differences between the studies allowed more variability in the rate calculation for fast
turnover proteins. Comparison against a published dietary heavy-labeled amino acid study24
also showed a strong linear correlation for the rates (Figure 2-4C). The rates as measured in the
Price et al. study tended to be slower as the turnover increased; this could represent a real
biological difference of slower trafficking of the labeled amino acids relative to deuterated water.
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2.6 Discussion
Measuring turnover of individual proteins in vivo is a critical first step towards
understanding how the cell modulates protein synthesis and/or degradation to maintain protein
homeostasis (proteostasis). Metabolic D2O labeling is an experimentally simple and inexpensive
method for monitoring protein turnover (See Table 2-S1 for advantages and disadvantages).
Although the data analysis is based on well understood combinatorial statistics25, the time
dependent calculations are different for each peptide. This creates an imposing data analysis
challenge for a proteomics data set and has impeded widespread use of the technique. Other
investigators have developed open source software for individual steps of the analysis1,2. Our
software platform, DeuteRater, simplifies the entire data analysis workflow with a user-friendly
GUI to enable proteome wide measurements of turnover. Importantly, DeuteRater is able to
utilize all of the ΔSx and ΔIx distribution information available in the isotope pattern (Figure 21). This results in 2n-1 (n=number of neutromer peaks, Figure 2-1 B) measurements of turnover
for each spectrum. Having multiple measurements allows precision to be quantified for each
peptide charge state. This creates a continuous determination of the measurement accuracy and
precision for each step of the experiment and analysis. We show here that both ΔSx and ΔIx can
provide in vivo kinetic information and quantify noise in the mass spectrometer, as a robust
metric to increase consistency.
As a simple example of the utility of these precision metrics, we compared the effects of
the Vendor-specific versus General centroiding algorithm the ProteoWizard1,2 application used to
prepare data for DeuteRater analysis. We observed that for a single data file more isotope
patterns were extracted from data centroided with the General algorithm, but that there was
decreased isotope envelope accuracy. We found that even for matched peptides, both ΔIx and
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ΔSx were less accurate in General centroiding than Vendor centroiding (Figure 2-S4). Therefore,
in subsequent data analysis steps, the Vendor-specific centroiding algorithm was used.
Using the peptide accuracy and precision metrics, we can also apply rational criteria to
the evaluation and optimization of instrument acquisition parameters. In our study, we tested
three different instrument models and 8 different m/z resolutions (Figure 2-S3). We found that
data accuracy was best when monitoring the relative neutromer intensity distribution (ΔIx) on the
QToF and the Orbitrap Fusion at low m/z resolution (60k, Figure 2-S5). The neutromer spacing
(ΔSx) was most accurate on the Orbitrap Fusion at 120k m/z resolution, but interestingly did not
improve with increasing mass resolution. We attribute this to the longer scan time for each duty
cycle and therefore fewer scans to average over the chromatographic elution. This suggests that
ΔSx is more sensitive to noise than ΔIx, consistent with the much smaller theoretical range for
ΔSx relative to the range for ΔIx (Figure 2-1). DeuteRater allows the user to decide whether to
choose whether ΔSx, ΔIx, or the combination is used to calculate rates. This choice should be
made based on the performance of the instrument. Although the matched peptide analysis
showed that the combination data was better for both the QToF and Orbitrap data (Figure 2-S5),
generally ΔSx was poor for the QToF data set (Figure 2-S3). Therefore, we use the ΔIx kinetics
for QToF data and combined for Orbitrap. Even for experiments that do not use metabolic
labeling, analysis of unlabeled peptide accuracy and precision is simple and fast in DeuteRater
and represents a good method for monitoring instrument performance and data quality (Figure 2S2).
We measured turnover rates for 90 proteins in blood serum, which is essentially the state
of the art for the number of proteins observed in whole blood plasma with these short (25
minute) LCMS gradients1-4. Multiple sample preparation and data acquisition steps could be
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modified to increase the breadth of proteome coverage. Although the number of proteins was
sufficient for this study, DeuteRater is currently being used to analyze proteome-scale data sets
consisting of thousands of proteins.
In the QToF data, which we are using as our standard of comparison, 56 of the observed
proteins had turnover rates with a covariance of less than 0.2. The rates ranged from 0.02 per
day, to faster than we could reliably measure with the tissue sampling intervals. Comparison of
the rates between analyses in this study and with published values1-4 showed that the turnover
rates are highly consistent. For example, the reported rates for Hemoglobin Alpha (P01942)
varied less than 20 percent between the studies. This suggests that the measurement of turnover
kinetics is highly reproducible and that the streamlined DeuteRater analysis provides high quality
results.
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3. Mechanisms of in vivo Ribosome Maintenance Change in Response to Nutrient Signals

3.1 Chapter Summary
As with the “DeuteRater: a Tool for Quantifying Peptide Isotope Precision and Kinetic
Proteomics” Chapter, this is the accepted manuscript of a published paper. As with the
“DeuteRater: a Tool for Quantifying Peptide Isotope Precision and Kinetic Proteomics” chapter,
the manuscript has been edited for formatting and clarity. This paper was published in issue 16
of Molecular and Cellular Proteomics doi:10.1074/mcp.M116.063255.
3.1.1 Authors in Order of Contribution
Andrew D. Mathis±, Bradley C. Naylor±, Richard H. Carson, Eric Evans, Justin Harwell,
Jared Knecht, Eric Hexem, Fredrick F. Peelor III, Benjamin F. Miller, Karyn L. Hamilton, Mark
K. Transtrum, Benjamin T. Bikman, John C. Price
±

These authors contributed equally to this work.

3.1.2 Contributions of Major Authors
My co-first author Andrew Mathis and I led the team responsible for animal care. I
performed the analysis of “Total Pool” ribosome data, and the final round of analysis on all
proteomic data. My co-first author Andrew Mathis led the “Assembled Pool” ribosome data and
follow up experiments such as the qPCR. We were both involved in initial rounds of data
analysis.
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3.2 Abstract
Control of protein homeostasis is fundamental to the health and longevity of all
organisms. Because the rate of protein synthesis by ribosomes is a central control point in this
process, regulation and maintenance of ribosome function could have amplified importance in
the overall regulatory circuit. Indeed, ribosomal defects are commonly associated with loss of
protein homeostasis, aging and disease, whereas improved protein homeostasis, implying
optimal ribosomal function, is associated with disease resistance and increased lifespan5,6,8,9. To
maintain a high-quality ribosome population within the cell, dysfunctional ribosomes are
targeted for autophagic degradation. It is not known if complete degradation is the only
mechanism for eukaryotic ribosome maintenance or if they might also be repaired by
replacement of defective components. We used stable-isotope feeding and protein massspectrometry to measure the kinetics of turnover of ribosomal RNA (rRNA) and 71 ribosomal
proteins (r-proteins) in mice. The results indicate that exchange of individual proteins and whole
ribosome degradation both contribute to ribosome maintenance in vivo. In general, peripheral rproteins and those with more direct roles in peptide-bond formation are replaced multiple times
during the lifespan of the assembled structure, presumably by exchange with a free cytoplasmic
pool, whereas the majority of r-proteins are stably incorporated for the lifetime of the ribosome.
Dietary signals impact the rates of both new ribosome assembly and component exchange.
Signal-specific modulation of ribosomal repair and degradation could provide a mechanistic link
in the frequently observed associations among diminished rates of protein synthesis, increased
autophagy, and greater longevity.

47

3.3 Introduction
Cells achieve protein homeostasis (proteostasis) by carefully balancing the synthesis and
folding of each protein against the protein degradation and cellular proliferation rates.
Controlled shifts in proteostasis occur during cell differentiation, and in response to stimuli10-13,
while uncontrolled changes promote neurodegenerative disease, cancer1,5,17-19, and aging. This
suggests that each cell coordinately regulates the ribosome, proteasome, and other key structures
of protein metabolism to achieve proteostasis. However, the regulatory mechanisms for
coordination, and how the proteome is remodeled to achieve a new proteostasis, are poorly
understood.
Diets restricting calories or amino acids (DR) protect against aging and the diseases of
aging, in model organisms5,6,19. Low calorie diets have been shown to reduce rates of protein
synthesis and degradation for much of the observed proteome2. Recent reports suggest that high
protein synthesis demand is associated with reduced ribosomal accuracy23 and efficiency24.
This suggests that maintaining ribosome quality is an intricate task that requires constant cellular
effort.
Translation rate is a metric of ribosome quality25. Ribosomes that stall during protein
production are immediately tested by the Ribosome Quality Control (RQC) complex26. The
RQC specifically tests the large subunit for activity27, and presumably sequesters inactive
ribosomes. Degradation of unnecessary or damaged ribosomes often occurs through directed
autophagy (ribophagy)28. Ribophagy is presumably one of the primary roles for autophagy,
indeed the earliest descriptions of autophagic vesicles show ribosomes in the interior29. An
important open question though is: Can dysfunctional ribosomes be repaired, or is ribophagy the
only option?
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Exchange of damaged ribosomal components could allow the cell to repair faulty
ribosomes instead of degrading the entire structure. The formation of new ribosomes is extremely
costly and has been estimated to account for 15% of the protein synthesis budget5,6,9,19. In yeast
protein synthesis accounts for at least 90% of the energy usage5,6,9,19. Damaged ribosomes in E.
coli have been shown to regain activity after exchange of ribosomal proteins (r-proteins) for
undamaged copies. Although it has never been demonstrated in eukaryotes, exchange of damaged
protein components could reduce the total energy expenditure to maintain active ribosomes.

Figure 3-1 Experimental Overview: Workflow for heavy isotope labeling, analyte isolation, and
measurement of turnover rates (A). Kinetic model for utilizing turnover measurements to describe ribosome
maintenance and turnover (B). Under these experimental conditions, opposing rates are equal maintaining
homeostasis.

Here we show that exchange of r-proteins is occurring in vivo. Using metabolic labeling
(Figure 3-1 A) and a kinetic model, we calculate exchange rates between assembled and free
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pools (Figure 3-1 B). Further, we show that r-protein exchange and ribophagy rates change with
dietary signals. We compare mice fed an ad libitum (AL) versus a restricted diet (dietary
restriction, DR), and observe that kinetically there are three groups of proteins in the assembled
ribosome. One group is never exchanged and is degraded via ribophagy with the rRNA. The
second group is exchanged multiple times with cytosolic copies and has members with either fast
or slow cytosolic turnover. A third group of proteins alternates between the first two groups.
We find that both ribophagy and r-protein exchange are modulated by dietary signaling. Our
observations offer insight into the connection between reduced protein synthesis, and increased
autophagy6 with increased health and longevity.

3.4 Methods
3.4.1 Mouse handling
Mice were housed, diet restricted, and metabolically labeled according to protocols
approved by the Brigham Young University Institutional Animal Care and Use Committee
(IACUC). Ten-week-old male C57BL/6 mice were obtained from Charles River Laboratories.
For the duration of the experiment, mice were housed in a specific-pathogen-free (SPF) facility
with 12-hour light/dark cycles. All mice were fed an ad libitum (AL) diet for 1 week with 3–4
mice per cage. AL consumption amounts were monitored during the first week. After one week
mice were separated and assigned to a dietary restricted (DR, n=20) or ad libitum (AL, n=19) fed
diet on Harlan 8604 chow. The DR cohort then received a metered 65% daily ration for the rest
of the study. The low-calorie diet used in this study restricted every component of the diet
equally, which classically is termed dietary restriction (DR). Mouse weights were recorded each
week. After 10 weeks of treatment, mice received an intraperitoneal sterile D2O saline injection
(35µL/g body weight) to immediately bring body water to 5% D2O as previously described 35.
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Drinking water was supplemented to 8% molar percent excess (MPE) D2O to maintain 5% body
water throughout the experiment. Mice (n=17) were sacrificed in duplicate (n=2) at time points
0 days (no D2O injection), 0.4 days, 1 day, 2 days, 4 days, 8 days, 16 days, and triplicate at 32
days. Mice were immediately dissected, blood was extracted by cardiac puncture for % D2O
analysis, and organs were either used fresh for mitochondrial respiration measurements or flash
frozen on blocks of solid CO2. Tissues were stored at -80 °C.
3.4.2 Mitochondrial respiration
Fresh liver tissue was quickly removed from exsanguinated mice and immediately placed
in ice-cold mitochondrial respiration buffer 05 (MiR: 0.5 mM EGTA, 10 mM KH2PO4, 3 mM
MgCl2-6 H2O, 60 mM K-lactobionate, 20 mM HEPES, 110 mM Sucrose, 1 mg/ml fatty acid free
BSA, pH 7.1) and trimmed of connective tissue. Tissue was gently separated and homogenized
under a surgical scope (Olympus, ST) to particles of around 1 mg. Homogenate was then
transferred to a tube with chilled MiR05 and 50 µg/ml saponin and rocked at 4˚C for 30 min,
then washed in MiR05 at 4˚C for at least 15 min before use. High-resolution O2 consumption
was determined at 37˚C using the Oroboros O2K Oxygraph. Before addition of sample into
respiration chambers, a baseline respiration rate was determined. After addition of sample, the
chambers were hyperoxygenated to ~350 nmol/ml. Following this, respiration was determined as
indicated. Lastly, residual oxygen consumption was measured by adding antimycin A (2.5 µM)
to block complex III action, effectively stopping any electron flow and providing a baseline
respiration rate.
3.4.3 Isolating assembled ribosomes
Separation of free ribosomal proteins and assembled ribosomes was performed using a
sucrose gradient as follows. Frozen liver, 62–215mg, from time points 0, 1 day, 4 days, 8 days,
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and 16 days was homogenized in polysome buffer (20mM Tris/HCl, 150 mM NaCl, 5 mM
MgCl2, 1 mM Dithiothreitol, 1:100 dilution protease inhibitor cocktail (Sigma), and 1% Triton
X-100) using a bead homogenizer: 30 seconds, 4 m/s, repeated 1–3 times depending on need.
Lysate was placed into a new Eppendorf tube and clarified by centrifugation at 20,000g for 20
minutes at 4 °C. After clarification, sample was decanted then ~300 µL was passed through a
2.2mL sucrose cushion (1M sucrose, 20mM Tris/HCl, 150 mM NaCl, 5 mM MgCl2, and 1 mM
Dithiothreitol) for 12 hours at ~200,000g (40,600rpm) 4 °C using a Ti-55 rotor on the Optima L100XP Ultracentrifuge (Beckman Coulter). After centrifugation, sucrose was decanted and the
ribosome pellet was suspended in 6M Guanidine/HCl, 100mM Tris/HCl pH 8.5.
3.4.4 Polysome analysis
The polysome analysis was patterned on the method of Zhao et al36. Sucrose density
gradients were prepared using 5 layers of buffered sucrose (50 mM Tris, 50 mM Ammonium
Acetate, 12 mM MgCl2, pH 7.0, and either 7%, 21%, 33%, 47% or 60% sucrose). 1 mL of each
mixture was placed in a centrifuge tube from high density (60%) at the bottom to low density
(7%) at the top. This step gradient was stored at 4° C overnight to allow formation of a
continuous gradient. The next morning flash frozen liver tissue was homogenized in lysis buffer
(15 mM MgCl2, 200 mM KCl, 1 % Triton x-100, 100 ug/mL cycloheximide, 2 mM DTT, .1%
diethyl pyrocarbonate, pH 7.4) at 6 m/s for 60 s in a MP-Biomedicals FastPrep®-24. The
homogenate was centrifuged to clarify (14,000 g, 5 min, 4° C). Approximately 1.2 mg of total
protein loaded onto each gradient. The sample was then separated within the sucrose gradient
using high speed centrifugation (99526 g, 4 hrs, 4° C) in a Beckman Coulter Optima™ L-100
XP. Polysomes analyzed using an Isco UA-6 Absorbance Detector at 254 nm. Six mice from
AL and six from DR were run in duplicate for assessment of polysome profiles.
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3.4.5 Mass spectrometry sample preparation
New DNA was measured as the isotope incorporation into the ribose moiety of the
nucleoside bases, as previously described6,37. New rRNA was also measured as the isotope
incorporation into the ribose moiety of the nucleoside bases, by adapting the GC-MS method to
follow the heavier ribose instead of the deoxy-ribose. DNA was isolated from tissue homogenates
using the DNEasy kit (Qiagen). RNA was extracted from the assembled ribosomes using the
Purlink RNA minikit (Life Technologies). rRNA was isolated by homogenizing liver tissue in
20mM Tris pH=7.2, 0.2M sucrose, 2mM MgCl2, 150 mM KCl, 1mM dithiothretol with protease
inhibitor cocktail (Sigma), Cycloheximide (Sigma). This homogenate was clarified by brief
centrifugation (10 minutes at 14,000 G). Clarified homogenate was spun at 100,000xG through a
1M sucrose cushion in the same buffer for 16 hours. The supernatant was discarded and the pellet
containing assembled ribosomes were resuspended using 100 µL 6M guanidine HCL pH=8.
Isolated RNA/DNA was hydrolyzed overnight at 37 °C with nuclease S1 and potato acid
phosphatase. Hydrolysates were reacted with pentafluorobenzyl hydroxylamine and acetic acid
and then acetylated with acetic anhydride and 1-methylimidazole. Dichloromethane extracts were
dried, resuspended in ethyl acetate, to be analyzed by GC-MS.
Assembled pool protein samples were prepared for protein mass spectrometry using
modified filter-aided sample preparation6,37. Briefly, protein was denatured in 6 M
Guanidine/HCl 100 mM Tris/HCl (pH 8.5), cysteines were reduced using dithiothreitol and
alkylated using iodoacetamide. Samples were placed on 500 µL 30kD filters and washed 2–3
times on the filters using 6 M Guanidine/HCl 100mM Tris/HCl pH 8.5. The guanidine solution
was removed by two to three 25 mM ammonium bicarbonate washes. Proteins were
resuspended in 25 mM ammonium bicarbonate and digested overnight using Pierce MS-Grade
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Trypsin in a 1:50 (w:w) ratio or minimum 0.1 µg or 0.5 µg of trypsin per sample. Trypsin digest
was quenched using phenylmethane-sulfonylfluoride (PMSF) or centrifuging through above
mentioned filters to remove trypsin. Samples were spun through filters, placed in mass spec
vials, speed vacuumed to dry, and then suspended at ~1 µg/µL in 3% acetonitrile 0.1% formic
acid.
Total pool samples were prepared from whole liver lysates protocols similar to ribosomal
samples. Liver was homogenized in a 100 mM ammonium bicarbonate solution with the
protease inhibitor cocktail (Sigma) aiming for a final concentration of approximately 10 mg/ml
protein concentration. Approximately 500 µg of protein was lysed in 6M Guanidine/HCl
100mM Tris/HCl and subject to similar filter-aided preparations and trypsin digestion as
described above. After digestion, samples were spun through filters, speed vacuumed to dry, and
resuspended in 10 mM LC-MS grade ammonium formate pH 9.5. Samples were fractionated
using high pH C18 high performance liquid chromatography (HPLC), which is orthogonal to low
pH C18 chromatography38. Fractionation was performed using the 1260 HPLC Infinity
(Agilent) and the Gemini 50 x 2.00 mm C18 column with 3 µm beads and 110 angstrom pore
size. Peptides were eluted using a 10 mM ammonium formate pH 9.5 H2O/acetonitrile gradient
from 3% B to 60% B over 40 minutes flowing at 1 mL/min. Gradient A is 97% H2O, 3%
acetonitrile, 10mM ammonium formate pH 9.5. Gradient B is 10% H2O, 90% acetonitrile,
10mM ammonium formate pH 9.5. 1 mL fractions were collected. 1 mL fractions were pooled
into 8 fractions by pooling every 8th fraction. For instance, fractions 1, 9, 17, and 25 would be
pooled into one fraction. Pooled fractions were speed vacuumed to dryness then suspended in
200 µL of 80% acetonitrile (to extract peptides but leave some salts) and decanted into a mass
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spectrometry vial. Samples were again speed vacuumed to dry and then suspended in 40 µL of
3% acetonitrile 0.1% formic acid for LC-MS analysis.
3.4.6 LC-MS proteomics acquisition
As described previously, protein identification and kinetic acquisition were performed on
the Agilent 6530 Q-ToF mass spectrometer coupled to capillary and nanoflow Agilent 1260
HPLC using the chipcube nano-spray source6,37. Peptides were eluted from the Agilent C18
Polaris chip at 300 nL/min using an H2O-Acetonitrile gradient acidified to pH 4 by use of Pierce
LC-MS grade formic acid. Buffer A was 3% acetonitrile, 0.1% formic acid. Buffer B was 97%
acetonitrile, 0.1% formic acid. The elution gradient is as follows: 0 minutes, 100% A; 0.1
minutes, 95% A; 27 minutes, 40% A; followed by high percentage B column washing and low
percentage B equilibration. The Agilent 6530 Q-ToF mass spectrometer was run in 2 Ghz high
dynamic range mode. Protein identification runs were performed in MS/MS mode using
collision induced dissociation with nitrogen gas. MS1 and MS2 data were collected at a
maximum rate of 4 spectra/second with CID fragmentation on the top 10 most abundant
precursors. Dynamic exclusion was set to 0.2 minutes. Kinetic acquisitions were performed in
MS-only mode and collected at 1 spectra/second. MS only mode increases signal intensity,
improves signal-to-noise, and gives more scan points per elution chromatogram greatly
enhancing isotopomer analysis accuracy. Raw data is available for download at the Chorus
Project (ID# 1148).
3.4.7 Peptide identification
Peptide identifications were made using SpectrumMill B.06 then overlaid onto kinetic
acquisitions. SpectrumMill searches were performed against the Uniprot Mouse database (122015, with 16,802/51,418 entries searched) with MS1 tolerance ±20ppm and a MS2 tolerance
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±50 ppm, cabomidomethylation (C) as a static modification, and pyroglutamic acid (n-term) and
oxidation (M) as dynamic modifications.
Searches were performed using trypsin as a digestion enzyme allowing 2 missed
cleavages at lysine or arginine. A second search with no specific enzyme was performed against
a restricted library of identified proteins. Following general recommendations from Agilent,
peptides with a score greater than 7 and greater than 60% scored peptide intensity were used for
further analysis. False discovery rate was calculated by the built-in algorithms of the Spectrum
Mill software, and was set at 1% for peptides and proteins. Identified peptides were exported
and used to calculate mass isotopomer distributions and extract peptide isotope patterns from
MS-only acquisitions (supplemental information).
3.4.8 Mass isotopomer and kinetic analysis
MS-only isotopomer data was extracted based on peptide identification from MS/MS
acquisition using m/z (± 12 ppm) and retention time alignment (± 0.8 minutes). Data extraction
and analysis was conducted using our DeuteRater39 software tool based on previous publications
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. Briefly, isotope peaks M0–M4 were normalized against the sum of the signal intensity, then

compared to theoretical calculations based on percentage D2O enrichment to determine fraction
deuterium enriched (new) peptide (as previously described37,39). Theoretical calculations were
determined using the EMass algorithm and based on the number of possible deuterium
incorporation sites per amino acid. The theoretical changes in abundance of each isotope peak
M0–M4 were compared against experimental changes at each time point in order to determine a
time dependent percentage of newly synthesized peptide reported for each isotope peak. Thus,
for each peptide there are up to 5 (M0-M3 for peptides below and M0-M4 for peptides above
m/z=2400) semi-independent measurements of the peptide turnover, as previously described6.
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We used the standard deviation between these measurements as a metric of the measurement
precision for that peptide. If peptide precision was low (i.e. standard deviation exceeded 0.1) the
data point was removed from downstream analysis (Figure 3-S2). Additional filters were also
applied to remove peptides with total relevant intensity below 20,000 counts and a retention time
deviation greater than 0.5 minutes.
The median percent new was calculated at each point and outliers (defined as greater than
1.4X the median absolute standard deviation) were removed from the calculation of the protein
percent new. All peptide measurements for an individual time point that passed these filters were
weighted equally in the calculation of the fraction new protein at that time point. As described
previously, the combined fraction new measurements were fit using a non-linear least squares
regression based on first-order kinetic rate equations34. The proteins with high precision data at
3 or more time points were fit according to first-order rate kinetics. We required 3 or more
labeled time points in order to increase the confidence of the rate constant (Figure 3-S2).

For

the regression fit, time point zero is set to 0% new, and is given a standard deviation of 0.05
based on the accuracy during long term performance of this instrument. The standard deviation
and confidence interval from these fits were used to compare protein and rRNA in subsequent
analysis. Coefficients of variance (standard deviation of the fit over the turnover rate) above 0.2
are considered high confidence fits.
3.4.9 rRNA turnover analysis
After running in scan mode, peaks were identified at m/z 212 and 433. From these it was
determined that the 212 had better peak shape, accurately predicted natural abundance in an
unlabeled sample, and was therefore used for subsequent analyses. Based on accurate mass and
isotope distribution we identified the fragment. Mass isotopomer calculations were performed
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on the fragment using EMass software based on 3 incorporated deuteriums. The monoisotopic
M+1, and M+2 were used was used for % new RNA analysis and errors. Two mice were
measured in triplicate at each time point. Rates and confidence intervals are solely based on
standard deviations from least squared fits to first-order rate kinetics. Data was fit using a
single-phase association curve in GraphPad Prism. Rates and confidence intervals are solely
based on standard deviations from least squared fits to first-order rate kinetics. Data was fit
using a single-phase association curve in GraphPad Prism.
3.4.10 Quantitative polymerase chain reaction
Quantitative polymerase chain reaction (qPCR) was performed using SYBR green on an
Applied Biosystems 7500 instrument. Reverse transcription was performed with the iScript
cDNA synthesis kit (Bio Rad) and SYBR green master mix (Bio-Rad). Primers: 18s rRNA
forward(CTTAGAGGGACAAGTGGCG) reverse(ACGCTGAGCCAGTCAGTGTA); 16s
Mitochondrial rRNA forward(CGAGGGTCCAACTGTCTCTT) reverse(GGTCACCCCAACC
GAAATTT); vRNA forward(GCTGAGCGGTTACTTTGACA) reverse(GTCTCGAACCAA
ACACTCATG); TATA forward(ACAGCCTTCCACCTTATGCT) reverse (GATTGCTGTA
CTGAGGCTGC). qPCR instrument parameters were as follows: Stage 1 (1 cycle) 50 °C for 2
minutes; Stage 2 (1 cycle) 95 °C for 15 seconds; Stage 3 (30–45 cycles depending on need), 95
°C for 15 seconds, 59 °C for 1 minute. Melt curves to determine product purity and efficiency
calculations were performed on all primer sets (supplemental data). qPCR primer efficiency was
calculated using Real-time PCR Miner 4.142,43. Relative concentrations were calculated using
method by Pfaffl, which corrects for differences in primer efficiency42,43.
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3.4.11 Calculation of exchange rate:
Using the kinetic model (Figure 3-1B), the rate of change for each protein in each pool
can be described mathematically as:
Free Pool:

𝑑𝑑�𝑃𝑃𝑖𝑖 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 �
𝑑𝑑𝑑𝑑

= 𝑘𝑘𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠ℎ − 𝑘𝑘𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑘𝑘𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑘𝑘𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = 0

(3-1)

Where Pi is an individual protein concentration, ksynth is the synthesis rate, kdeg is the degradation
rate, kadd is the rate of proteins adding to the assembled ribosome, while kremove is the rate of
proteins leaving the assembled ribosome and reentering the free pool.
Assembled Pool:

𝑑𝑑[𝑃𝑃𝑖𝑖 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 ]
𝑑𝑑𝑑𝑑

= 𝑘𝑘𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑘𝑘𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟ℎ𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑘𝑘𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑘𝑘𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 = 0

(3-2)

Where in addition to the terms above, kassemble is the apparent rate of formation and export of the
intact active ribosome from the nucleolus to the cytosol. kribophagy is the rate of whole ribosome
degradation; this includes both protein and rRNA.
Ribosome pool:

𝑑𝑑[𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟]

Total protein pool:

𝑑𝑑[𝑃𝑃𝑖𝑖 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ]

Exchange rate:

𝑑𝑑[𝑃𝑃𝑃𝑃]

𝑑𝑑𝑑𝑑

𝑑𝑑𝑑𝑑

𝑑𝑑𝑑𝑑

= 𝑘𝑘𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑘𝑘𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟ℎ𝑎𝑎𝑎𝑎𝑎𝑎 = 0

=�

=

𝑑𝑑�𝑃𝑃𝑖𝑖 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 � 𝑑𝑑�𝑃𝑃
�
+ 𝑖𝑖 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

2

𝑑𝑑[𝑃𝑃𝑃𝑃 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎]
𝑑𝑑𝑑𝑑

−

𝑑𝑑[𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟]
𝑑𝑑𝑑𝑑

3.4.12 Experimental Design and Statistical Rational

=0

� = 𝑘𝑘𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑘𝑘𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = 0

(3-3)
(3-4)
(3-5)

There were 2 biological replicates for each time point in each kinetic pool measurement
(assembled/total) of each diet (AL vs DR). Each kinetic rate was determined by up to 10
biological replicates, so no technical replicates were included. A minimum of three time points
were required to fit a rate constant, because with three time points the rates are well constrained
(Figure 3-S2). As described above, peptide measurements were included if they met the
retention time and precision filters. Statistical analysis and graphing was performed using
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GraphPad Prism and the Numpy software package. GraphPad Prism was used to fit the DNA to a
first order kinetic38 and rRNA to a second-order kinetic6 as previously described, and to calculate
95% confidence intervals. An in house Python tool termed DeuteRater45 was used to calculate
the fraction new peptide, fit the protein turnover rates to a single pool model using first-order
rate kinetics, and calculate 95% confidence intervals. If rates were outside of the 95%
confidence interval of rRNA or another protein they were considered significantly different.

3.5 Results
3.5.1 Short term dietary restriction (DR) elicits the canonical physiological changes associated
with lifespan extension
Restricted mice (n= 18) lost weight relative to AL controls (n=18) for the first two weeks
of the restricted diet, after which they gained weight at a rate similar to controls (Figure 3-2 A).
In order to ensure that both the AL and the DR mice were at homeostasis, the dietary treatment

Figure 3-2 Short-term DR elicits the classic physiological and biochemical adaptations associated with
lifespan extension: After an initial weight loss, DR mice continued to gain weight at a reduced rate (A).
Liver cell proliferation was reduced (p<0.01) from 0.04% per day to 0.03% per day (B). DR reduces
mitochondrial respiration, samples were treated with: GM: Glutamate (10 mM) + Malate (2 mM); +
ADP (2.5 mM Adenosine diphosphate); +Succ: (Succinate 10 mM). Respiratory control ratio (RCR;
inset) was unchanged (C).

was continued for 10 weeks prior to initiating the metabolic labeling experiment (Figure 3-1).
Using previously described methods5, we found that the cell proliferation rate was reduced 25%
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(p<0.05) in DR (Figure 3-2 B). Consistent with previous reports, we observed liver tissue
respiration capacity was decreased by DR5,6, for both complex 1 and complex 2 driven electron
transport (Figure 3-2 C). Respiratory efficiency, which is the ratio of the ADP dependent O2
usage (+ADP) versus non-specific oxygen usage (Glutamate+Malate), was not changed (inset to
Figure 3-2 C).
3.5.2 Ribosome activity is reduced during DR
Similar to published protocols5,6, we used a sucrose gradient to separate out the various
ribosome states within the liver tissue of AL and DR animals (Figure 3-1). Polysome analysis
(Figure 3-3 A) was conducted twice on 6 animals from each diet group, and the normalized area
under the curve of each ribosomal species was quantified. The number of ribosomes actively
transcribing mRNA (polysomes) was significantly lower (p<0.05) in DR tissue (Figure 3-3 B).
Interestingly, the total number of ribosomes, as measured by qPCR, was not significantly
changed by DR (Figure 3-S1). These combined results suggest that during DR a lower
percentage of available ribosomes are actively producing protein, similar to previous reports34.

Figure 3-3 Short-term DR reduces percentage of active ribosomes: Representative data from polysome
analysis in which a density gradient separates individual subunits from active ribosomes in both AL and
DR tissue (A). Quantitation of the populations suggests that DR increases the free 40S state by
significantly decreasing the number of active polysomes (Poly 3 in panel B) Comparison of turnover
rates for 1050 matched proteins showed a statistically non-significant general reduction of protein
turnover rates in DR. (C)

We also compared ribosome activity by measuring turnover (synthesis + degradation)
rates for 1050 proteins observed in both AL and DR (Figure 3-3 C). Consistent with previous
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investigations of changes in protein turnover during low calorie diets, we observed that during
DR the median protein turnover rate was 5% slower (Figure 3-3 C). This decrease is smaller
than in previously reported studies42,43,46, and not statistically significant. We are currently
investigating how specific components of the diet may have modified regulation of global
protein homeostasis during lower calorie intake. Together these results suggest that the overall
ribosome pool has slightly reduced activity with more ribosomes in the cell as dissociated
subunits in DR tissue.
3.5.3 Turnover rate of the rRNA backbone is slightly faster in DR tissue
Assembled ribosomes were isolated from the liver tissue of 2 animals at each of the 8
time points and separated into two samples for analysis of rRNA and r-protein turnover (Figure
3-1 A). New rRNA was measured as the isotope incorporation into the ribose moiety of the
nucleoside bases, similar to the accepted method for measuring DNA synthesis. The fraction
new rRNA increased exponentially with time (Figure 3-4). Previously, rRNA modeling has
shown that in rapidly dividing cultures incorporation of a precursor pool improved model
accuracy47. We compared both the single pool and the precursor model for fitting the rRNA
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Figure 3-4 rRNA turnover measures eukaryotic ribophagy: Deuterium incorporation into the ribose of
the rRNA bases is not significantly slower in AL (10.1±1.2% Day-1) than the DR (11.1±1.7% Day-1).
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sized of 13% and 6% for AL and DR tissue respectively. We observed a non-significant increase
in rRNA turnover in the DR tissue (11.1±1.7% Day-1) relative to AL tissue (10.1±1.2% Day-1).
We checked whether mitochondrial ribosomes are a potential source of contaminating
rRNA (Figure 3-S1). Protein mass spectrometry of the isolated ribosomes confirmed that minor
amounts of mitochondrial r-proteins were present. Mitochondrial r-proteins share little or no
homology with the eukaryotic ribosomes and therefore cannot confound the measurement of
protein kinetics. As measured by our assay, mitochondrial rRNA cannot be differentiated from
eukaryotic rRNA. Therefore, in order to determine the effect of mitochondrial rRNA on
measured ribophagy rates, we isolated ribosomes both with and without non-ionic detergent.
With detergent, we measured a relative 5-fold higher concentration of eukaryotic ribosomal
rRNA. Without detergent, the total ribosomal isolation was less efficient, but the amount of
eukaryotic 18S to mitochondrial 16S rRNA as measured by qPCR increased 50 percent (Figure
3-S1). The large relative change in the mitochondrial content did not change our rates of rRNA
turnover in these samples (Figure 3-S1), indicating that the absolute contamination from the
mitochondrial ribosome rRNA is relatively minor, and does not bias our results for cellular
rRNA and ribophagy rates.
Simple stoichiometry of the rRNA within the cell supports the conclusion that
mitochondrial contamination will not bias rRNA rates. Based on studies in yeast, there are
approximately 14 times more eukaryotic than mitochondrial ribosomes6,37,49. The eukaryotic
ribosome contains approximately 3 times the number of rRNA bases. Therefore, the rRNA bases
from eukaryotic ribosomes are about 42-fold more abundant than mitochondrial, which suggests
that the rRNA turnover rate will dominated by the eukaryotic ribosomes. Our sample
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preparation also removed many of the mitochondria prior to ribosome isolation and should
further bias the sample towards eukaryotic ribosomes.
3.5.4 Dietary Restriction significantly changes the turnover rates of proteins in the assembled
ribosome
Similar to our previous studies, isotope incorporation into multiple tryptic peptides was
measured for each protein in multiple samples along the time-course42. We isolated assembled
ribosomes for analysis of r-protein turnover (Figure 3-1 A). Turnover rates were significantly
different between the individual r-proteins (Figure 3-6 A); we measured turnover rates for 71 of
the 80 integral r-proteins with turnover rates ranging from 4-25% per day (Supplemental Table
3-S1). Interestingly, the median turnover rate for the entire group of r-proteins in the assembled
ribosome is the same as the rRNA turnover rate (0.10 Day-1 in AL, 0.11 Day-1 in DR).
Comparison of the individual protein turnover rates to the rRNA rate shows that many
(approximately 80%) of the proteins turnover within two standard deviations of the rRNA rate
(Figure 3-5 B, C, and D, grey symbols). This suggests that the rRNA and these proteins may all
be synthesized and degraded together as a unit, as occurs during ribophagy. In addition, the
large number of individual protein measurements makes the DR-dependent increase in ribophagy
statistically significant (Figure 3-5 D, p<0.0005).
DR also increased the observed range of rates within the assembled ribosome, but the
rRNA turnover confidence interval (CI, defined as 2 standard deviations) was also wider so the
percentage of non-exchanging proteins stayed around 80%. The proteins at the 60S/40S
interface (L10, L36A, L24, L34, and L19) were still among the fastest turnover proteins within
the assembled ribosome, and were replaced faster than the rRNA CI (Figure 3-3 D). Although
there were several proteins slower than the rRNA CI in both AL and DR, these proteins were not
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the same in both groups (Figure 3-5 D). Importantly, each of these protein turnover rates was
calculated from multiple measurements of multiple peptides.
3.5.5 Turnover for most r-proteins is not different between the Assembled and Total Pools

Figure 3-5 Turnover rates of r-protein are equivalent between pools, but not between dietary

groups: Individual ribosomal proteins turnover at different rates within the assembled ribosome (A),
but have the same rate in both assembled and total pools (B, C). Approximately 80% of r-protein
turnover rates (gray circles) are within the confidence interval of the rRNA (red). R-Proteins with
unusually fast or slow turnover (black circles) were observed in both AL (B) and DR (C) tissue.
Comparison of assembled AL and DR (D) showed that some of the outlier proteins are the same in
both conditions.

We were not confident that we could keep assembled and free pools separate during
tissue homogenization. Therefore, we measured the total pool (free + assembled) and assembled
pool turnover. The turnover rate within the total cellular lysate represents the average of the free
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and assembled protein pools (Equation 3-4). A deviation between assembled and total pool
turnover rates could indicate that exchange is a rate limiting process. Generally, we observed
that there was no statistically significant change in turnover between assembled and total protein
pools regardless of dietary intervention (Figure 3-3 A and B). Individual proteins had altered
turnover in either AL or DR mice, but not in both. Experiments in E. coli suggest that greater
than 95% of the r-proteins in the cell are bound in the ribosome structure51. A mass averaged
turnover measurement would suggest that the total pool rate should reflect the assembled pool
similar in these measurements.
3.5.6 Calculation of r-protein exchange rates
A kinetic model for ribosome biogenesis and maintenance was used to compare the
turnover of the assembled and total r-proteins and to calculate the exchange between pools
(Figure 3-1 B). We measured the relative concentration of the rRNA by qPCR between
experimental cohorts and did not see a significant change. The unchanged rRNA concentration
and the steady rate of weight increase (Figure 3-2) after the 10 weeks of dietary acclimation
reinforces the conclusion that these proteins are at a condition of homeostasis. Therefore, under
these conditions, the total concentrations are constant and the opposing rates of synthesis and
degradation are balanced (i.e. kadd is equal to kremove).
Using the kinetic model, the rate of change for each protein in each pool can be described
mathematically as shown in supplemental methods. We have directly measured the turnover of
the rRNA, which represents the turnover of the ribosome as a unit (Equation 3-3). We also
measured the protein turnover rate within the assembled ribosome (Equation 3-2, kassemble + kadd,
note that kassemble = kribophagy and kadd = kremove due to homestasis) and the total pool (Equation 3-4,
ksynth + kadd, noting that ksynth = kdeg and kadd = kremove). We therefore calculate the exchange rate
66

(kadd and kremove) as the absolute value of the difference in turnover rates of the assembled pool
and the rRNA (Equation 3-5: Figure 3-1 B).
This calculation suggests that the greater the difference between r-protein and rRNA the
faster the exchange rate. We therefore define all proteins more than two standard deviations
from the rRNA rate (outside the confidence interval or CI, black symbols, Figures 3-5 B, and C)
as fast exchange with the cytosolic pool (Figure 3-6 A). This separates the r-proteins into
essentially three groups: 1-Static, 2-rapid exchange-fast turnover, as well as rapid exchange-slow
turnover proteins, and 3-proteins that switch between groups 1 and 2. Static proteins are
integrated into the ribosome during initial assembly and are degraded with the assembled unit by
ribophagy (Figure 3-5 A gray circles within the square, ~80% of the r-proteins are in this group).
The fast exchange proteins (triangles in Figure 3-5 A) can be divided into two groups, fast
exchange - fast turnover proteins (12%), and fast exchange - slow turnover proteins (8%).
In DR tissue, there were slight differences in the identity of the individual r-proteins, but
a similar percentage distribution of proteins. Proteins L3, L10, L38, L24, and S27-like were still
fast exchange. This suggests that these proteins are rarely degraded by ribophagy and exchange
is intrinsic to the operation of the ribosome. Proteins L19 and L34 are still at the fast end of the
range, but fail to exceed the confidence interval of the rRNA. This suggests that L19 and L34
are not exchanged as frequently during DR, but that ribophagy plays a larger role in defining
their lifetime.
Of the fourteen fast exchange proteins observed in the AL ribosome, twelve either were
at the interface between subunits or have significant surface exposed to the cytosol. Seven of
these proteins were fast exchange in both DR and AL ribosomes. Rapid exchange proteins with
fast turnover tend to be located at the interface between the 60S and 40S subunits, and are
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involved with the structural motions of catalysis22. For example, L24, L34, and L19 bridge the
interface between the 60S and 40S ribosome (Figure 3-6). They hold the subunits together and
participate in the rotation between subunits during peptide bond synthesis2. Other fast turnover
proteins L10 and L36 also have an active role in the formation of new peptide bonds, and are
close to the interface between the subunits (Figure 3-6 B). Protein L38 is also part of this group,
but its function is less well understood and may play a role in mRNA substrate selection29.
Although there were a variety of rapid exchange proteins with slow turnover in either AL, or DR,
only L3 was rapid exchange under both conditions.

Figure 3-6 In vivo exchange of r-proteins: Most r-proteins exchange slowly (gray circles) and are

within the expected range for ribophagy (yellow box in A). Exchange rates for some r-proteins is outside
of the expected ribophagy rate in one condition (gray circles outside in white field for AL or DR). Some
exchange rates are rapid enough that these proteins are rarely degraded by ribophagy and instead are
degraded in the free pool (triangles). Some members of this group have slow cytosolic turnover (A, open
triangles), others have fast cytosolic turnover (A, closed triangles). (Panel B) Slow exchange proteins
(tan) cover the majority of the ribosome structure. Fast turnover/fast exchange r-proteins (closed
triangles) are primarily at the interface between 60S (gray rRNA) and 40S (black rRNA) subunits (red
proteins, model PDB: 4UG0).

In AL ribosomes, L35a and slow turnover L7 were fast exchange but do not follow the
structural trend of surface exposure. In the ribosome crystal structure (PDB: 4UGO), they both
seem to be buried underneath large rRNA loops and slow exchange proteins. Interestingly, they
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are next to each other in the structure, suggesting that the rRNA may be displaced to allow
exchange of these proteins simultaneously.

3.6 Discussion
The ribosome is a multi-megadalton complex of RNA and protein that synthesizes most
proteins in the cell. High demand for protein synthesis reduces ribosome efficiency4 and
accuracy2,52. In bacteria, damaged ribosomes can regain activity by replacement of damaged rproteins in the assembled structure with undamaged cytosolic copies2,52. Exchange of r-proteins
may also be important to the functional integrity of the ribosome in eukaryotes5,6, although this
idea is controversial. Metabolic labeling affords a means to evaluate this hypothesis by testing
directly for the replacement (turnover) of ribosomal components in vivo. We used metabolic
deuterium incorporation rates to compare turnover of ribosomal RNA (rRNA) and the individual
r-proteins in the assembled ribosome in mice (Figure 3-1 A). We also tested whether dietary
restriction (DR), which has previously been shown to modulate rates of ribosome biogenesis,
assembly, and activity in cells5,6 and mice42,43, can impact r-protein exchange rates.
Components of the ribosome reside in two kinetically distinct pools (Figure 3-1 B), with
different synthesis and degradation rates for the assembled complex and its individual
constituents5,6. At homeostasis, the rates of opposing steps in the model (e.g., assembly and
ribophagy) should be equal (Figure 3-1 B). Physiological and biochemical metrics of the DR
effect verified that the mice used in these experiments were at homeostasis (Figure 3-2) prior to
metabolic labeling, similar to previous studies53,54. The model also assumes that free rRNA,
without r-proteins, is degraded rapidly relative to the turnover of the assembled structure, as
observed previously6,37,49. Under this assumption, turnover of rRNA reflects only turnover of the
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assembled ribosomes (Equation 3-3). Turnover of r-proteins in the assembled pool would
depend on the kinetics of both assembly and exchange (Equation 3-2, kassemble + kadd, note that
kassemble = kribophagy and kadd = kremove due to homeostasis). We therefore calculated the exchange
rate (kadd and kremove) as the absolute value of the difference in turnover rates of individual rproteins (Pi) in the assembled pool and the rRNA (Equation 3-5: Figure 3-1 B).
Assembled ribosomes isolated from the liver tissue of two animals at each of eight time
points after introduction of the metabolic label were separated into two samples for analysis of
rRNA and r-protein turnover (Figure 3-1 A). The amount of new rRNA increased exponentially
with time (Figure 3-4) and could be modeled by assumption of a single pool. There was a
statistically insignificant increase in rRNA turnover increased in the DR tissue [(11.1 ± 1.7)
%•Day-1] relative to control with no dietary restriction (Ad libitum or AL) tissue [(10.1 ± 1.2)
%•Day-1]. In DR, although fewer ribosomes were actively translating protein (Figure 3-3), the
total number was not different between AL and DR tissue (via qPCR, Figure 3-S1 B). The
results imply that, on average, ribosomes were less active and had a slightly shorter lifetime (6
Days) in tissues of DR animals than in those from the AL animals (7 Days). The measurements
of protein turnover within the assembled ribosome and the observed proteome support these
results.
Turnover rates of the individual ribosomal proteins (r-proteins) were resolved by
monitoring incorporation of deuterium into multiple tryptic peptides for each protein along the
labeling time-course (Figure 3-5A), as previously described55. Within the set of 71 (out of 80
total) integral r-proteins monitored, a range of 4-28% per day was observed (Supplemental Table
3-S1). Most r-proteins turn over at rates that are similar to (within two standard deviations of)
that of the rRNA (Figures 3-5 B, C, D grey symbols), implying that this large group of r-proteins
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and the rRNA are replaced together as a unit (i.e., complete degradation of the complex). Indeed,
the average rate for the r-proteins (10.2% in AL and 11.3% in DR) matched the ribophagy rate
(10.1% in AL and 11.1% in DR) remarkably well. Comparison of resolved turnover rates of the
individual r-protein components (Figure 3-5 D) makes it apparent that the small DR-dependent
increase in rRNA turnover (Figure 3-4) is significant (p<0.0005). Overall, ~80% of r-proteins,
had individual turnover rates which match the ribophagy rate (within 2 standard deviations of the
rRNA). This agrees with earlier studies of average rRNA and r-protein turnover.
The increased rate of ribophagy in DR tissues was surprising. In agreement with
previous studies we observed that DR slows cell proliferation (Figure 3-2B) and protein
synthesis (Figure 3-3). Interestingly, the cellular half-life (169 days in AL) is 25 times greater
that the ribosome half-life in AL. In DR, the ribosome turnover is accelerated relative to cell
proliferations, becoming 37 times greater. The two-dimensional comparison suggests that the
rate of ribophagy, specifically, doubles relative to the rate of other processes like mitochondria
specific degradation or cell division. The up-regulation of ribophagy during DR, may explain the
previous observation that increased autophagy and lower protein synthesis rates work together to
improve cellular fitness and whole organism lifespan.
Although the turnover rate of r-proteins averaged over the entire set reflects the
ribophagy rate (as previously reported), a small but intriguing set of r-proteins have significantly
different turnover rates (Figures 3-5 B, C, and D, black symbols). Importantly, some of the
proteins with unusually fast or slow turnover are the same in both AL and DR tissues (Figure 3-2
D). The parallel behavior of these proteins in both dietary cohorts suggests that the difference in
their turnover rates might be intrinsic and functionally relevant. The difference in turnover may
be due to the free pool r-protein turnover rate (Figure 3-1 B), which is independent of the
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ribophagy rate. The free pool turnover rate is difficult to measure directly, since it is very low
concentration for each r-protein4,50, and homogenizing the tissue is likely to break assembled
ribosomes, contaminating the free pool. However, as shown in equation 3-5, the exchange rate
of each protein can be calculated without direct measurement of the free pool. The proteins that
are exchanged rapidly out of the assembled structure would have turnover rates defined by the
free pool. Therefore, fast exchange between the assembled and free pool could explain outliers
at both the fast and slow end of the turnover range (Figure 3-5).
When we compared the calculated exchange rates (Figure 3-6 A) against the ribosome
structure, we saw that the fast exchange and fast turnover r-proteins are predominately located at
the interface between the 60S and 40S subunits (Figure 3-6 B). This region is known to undergo
significant movement during the catalytic activity of the ribosome4,50. There are at least two
possible hypotheses to explain why ribosomal maintenance would include fast exchange of these
proteins. First: proteins at this location may be more prone to damage and therefore exchange
more rapidly. Second: damage of these proteins dramatically reduces formation of the 80S
ribosome and ensures that there is a longer exchange period. Three of these proteins (L19, L24
and L34) are structurally important, acting like long fingers to secure the 40S to the 60S subunit
(Figure 3-6). The other members of this subgroup (L10, L36A, and L38) are also localized in the
interface, either on the beak or directly across from it. Breaking the 80S down to the 40S and
60S could facilitate exchange of these proteins due to lost surface interactions and greater access
to the cytosol.
Cytosolic RPL36a and L10 are critical to formation of the P-site during assembly, and
guide the structural rotation necessary to form each peptide bond6,18. Dysfunction of these and
other fast exchange proteins is associated with disease6,18; therefore, exchange may represent an
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important method to maintain ribosomal quality. Greater exchange of these proteins in AL tissue
relative to the ribophagy rate may indicate that damage to these specific proteins occurs prior to
ribophagy.
One interpretation of these results is that ribophagy and r-protein exchange are both used
to maintain the active pool of ribosomes (Figure 3-7). Simplistically, the high synthetic demand
and longer lifespan for individual ribosomes observed in AL tissue might result in accumulation
of damaged ribosomes, as only a few selected proteins can be repaired. Slower cell proliferation
in DR suggests that, because there is less dilution into new cells, protein degradation is up
regulated to match synthesis22. Lower synthetic demand with an accompanying increase in
ribophagy, would allow for more extensive turnover of the assembled ribosome pool. Better
maintenance of the ribosome might lead to higher quality nascent peptides and improved

Figure 3-7 In vivo ribosome maintenance requires ribophagy and r-protein exchange: Each day,
approximately 10% of the ribosomal pool is replaced via assembly of new ribosomes and ribophagy.
During the lifetime of the assembled ribosomal structure, ribosome protein exchange occurs primarily
when the ribosome disassociates to its individual subunits. This exchange may be a fast, low cost, method
to repair and modify ribosomes. Cellular energetics and demand for protein synthesis may modulate the
relative contribution of ribophagy, versus exchange in response to stalled or damaged ribosomes.
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accuracy5,6,8,9 and efficiency relative to AL tissue. This provides an attractive interpretation for
the frequently observed connection between lower rates of protein synthesis, increased
autophagy, and improved protein homeostasis and longevity.
It has been observed that the ribosome quality control (RQC) complex is required to
dissociate stalled 80S ribosomes2. Our data suggests that ribosomes exchange components most
rapidly when dissociated into subunits, potentially after the RQC has dissociated the complex.
These results raise several interesting questions about mechanisms for maintenance. Is there
cross talk between RQC activity and ribosome component turnover? What factors control
ribosome component exchange? We assume a passive model, but could the RQC coordinate
active exchange? Proteins L35a and L7 are fast exchange in AL tissue, but are buried within the
rRNA. These proteins may require outside assistance to facilitate exchange. Finally, does rprotein exchange improve the quality of nascent peptides? Initial results suggest that reducing
global protein synthesis may improve protein quality3. Further investigation is needed to
confirm whether ribosomal maintenance is a mechanistic link explaining how lower protein
synthesis burdens are connected to improved protein homeostasis and lifespan.
In conclusion, this work uses a generally applicable strategy for investigating cellular
maintenance of the proteome, including multi-protein and ribonuclear structures. Here we show
that exchange of protein components and degradation of the entire ribosome are important
maintenance strategies. Our results suggest a mechanism wherein dissociation of 60S and 40S
subunits promotes in vivo r-protein exchange. We find that dietary signals can change both
ribophagy and r-protein exchange rates. Future work testing biological models which modulate
the RQC activity and/or mTOR signaling will test whether this is mechanism is generally
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applicable. In addition, linking changes in longevity to the rates of protein synthesis and
autophagy as we have done may help identify mechanisms of aging.
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4. Creation of Software Tools and Methods for Measurement of Kinetic Proteomics in
Humans

4.1 Chapter Summary
Unlike the previous two chapters, this work has not been published. I have written this
work in the form of a paper for consistency. The Future Directions section at the end of the
chapter indicates how the work is proceeding to bring the software and data to publication
quality. The basis of this work is modifications of the DeuteRater program required to analyze
data from kinetic proteomic experiments using humans as subjects.
4.1.1 Authors in Order of Contribution
Bradley C. Naylor, Marcus Hadfield, David Parkinson, Austin Ahlstrom, Austin
Hannemann, Paul Hafen, John Dallon, Rob Hyldahl, and John C. Price.
4.1.2 Contributions of Major Authors
I led making the adjustments of DeuteRater, led the human experiment, and prepared and
analyzed the samples by mass spectrometry. Other authors assisted in the human experiment
design, collecting samples from the subjects, wrote parts of the updated program, and providing
insight into differential equations to model the data.
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4.2 Abstract
Turnover for 1000’s individual proteins can be measured simultaneously using kinetic
proteomics methods, which monitor metabolic incorporation of an isotopic label over time.
Metabolic labeling using 2H2O has several experimental advantages for kinetic proteomics and
has been used in a variety of organisms from cells to humans. We previously published a
software tool, DeuteRater, that facilitates analysis of 2H2O-based kinetic proteomics
experiments. However, large animals such as humans often require experimental changes from
metabolic labeling methods for small animals or cell culture. Although DeuteRater offered
several improvements upon available software tools, it could not utilize data from these large
animal experiments. Therefore, we have developed a new software tool called DeuteRater-H,
which improves upon current calculation techniques for human kinetic proteomics and is an open
source software tool to perform kinetic proteomic analysis on human subjects.

4.3 Introduction
Living cells are dynamic systems. They constantly create new proteins and destroy old
proteins based on protein damage4,5, circadian rhythms6, changing environmental conditions7,
and normal maintenance1,3,8-11. The proteome scale study of protein turnover rates is called
kinetic proteomics. Kinetic proteomics measurements of normal conditions can reveal
interesting maintenance programs, such as differential replacement rates of proteins in a large
protein complex11. Kinetic proteomic analysis of different biological conditions can yield
information about how diseases affect cells, or even discover changes in protein turnover that
can function as biomarkers12,13. Due to the amount of information provided by the technique,
there is a need to provide easy-to-use, open source software for kinetic proteomics in clinical
settings2,3.
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Figure 4-1: Experimental Workflow. Basic kinetic proteomics experimental workflow used in this study.

Humans are provided with D2O, which is incorporated into amino acids and proteins. Biological
samples can then be taken, and proteins digested into peptides. The peptides are analyzed by mass
spectrometry and DeuteRater-H can then be used to turn the measured isotopic differences into a protein
turnover rate.

Kinetic proteomics has several advantages that make it ideal for human studies.
Important metabolic insights can be gained from proteins that are relatively abundant and easily
accessible10,12,13, and the workflow is relatively simple (Figure 4-1). A heavy isotope label,
generally deuterium in the form of deuterated water (D2O), is provided to the subject. The heavy
label is incorporated into bio-synthesized molecules in the organism, such as non-essential amino
acids. The labeled amino acids are used to synthesize proteins, resulting in new proteins
containing extra heavy isotopes. The shift in signal intensity and mass spacing between the
different isotopic populations of a peptide, called neutromers, is easily measurable by mass
spectrometry and the percent protein replacement or turnover can be calculated1,3.
The basic idea of kinetic proteomics has been around since the early 1990s14,15 and
deuterated water labeling has been used for proteomics since 201116. However, while studies
have been performed in humans, there are no open source software tools available to perform the
analysis. Although we1, and others16,17 have made software and algorithms to analyze kinetic
proteomics data in experimental animals, the requirements for working with human subjects
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complicate the analysis. Most methods of heavy labeling other than D2O require complete
dietary control8,18 or intra-venous infusion19, which are often impractical in humans. However,
rapidly changing D2O enrichments can cause vertigo20,21, therefore humans studies cannot follow
the protocol of rapid enrichment used for animal studies. Low deuterium enrichments (below 1
molar percent excess) can be used to limit vertigo, but low isotopic enrichment reduces signal to
noise, making turnover rates difficult to measure. To avoid the deuterium-dependent vertigo
while still obtaining acceptable signal, a steadily increasing enrichment is administered over
several days (Figure 4-2 A-B). This introduces a problem. The deuterium enrichment is used to
determine the maximum theoretical change in the neutromer peaks of each peptide. Knowing
the maximum theoretical change allows the experimental change to be expressed as a percentage
(Figure 4-2 C). If the enrichment is changing, the calculations become much more complex
because the maximum theoretical change in the neutromer peaks shift with each additional
protein replaced in the population (Figure 4-2 D).
In order to handle this problem, it is necessary to use a differential equation to combine
the equation for fitting the subject’s deuterium enrichment with the equation for the change in
isotopic abundance or spacing from the unlabeled baseline (Figure 4-3). Previously the
equations were limited to a rise to plateau enrichment curve and only using the mono-isotopic
peak for rate determination2,3. Now we need to allow for the increased complexity in enrichment
and isotopic measurement.
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Figure 4-2 Differences in Analysis between Animal Models and Humans: In a small animal,

such as a mouse, a Constant Enrichment model can be used with a greater percent of body
water being replaced with deuterium (Panel A). A large intraperitoneal bolus injection is used
to bring the animal instantly to the desired level of deuterium, where they are maintained for
the duration of the experiment. In humans, due to issues of vertigo from deuterium and the
impracticality of large intraperitoneal injections in human subjects, the deuterium label is
applied over time, creating an increasing enrichment, generally in the form of a rise to plateau
kinetic (Panel B). The enriched percent of body water is also lower in a human due to the
larger amount of water in a human. The calculation for Fraction new protein for a constant
enrichment experiment is relatively simple (Panel C). The distance between the isotopic height
at no labeling (blue line) to the isotopic height measured at a certain time (black lines) is
compared to the distance between the isotopic height at no labeling and the isotopic height
when all proteins are labeled (red lines). Since all points are constant (red and purple points in
panel A), this calculation is the same at all time points, save for the experimentally measured
component. If the enrichment is changing, the enrichment at an earlier time is less than the
enrichment at a later time (purple and red dots on Panel B), the enrichment for proteins
produced at those times is different (purple and red lines on panel D). Thus, the black lines in
panel D are a combination not just of unlabeled and labeled populations, but unlabeled and
many different labeled populations. Since only the average of all these populations is observed
in the mass spectrometer, a method of deconvolution is necessary for the data to be interpreted.
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Figure 4-3 Differential Equation Analysis. This represents the basic principle of the analysis. Dots are
actual data, and the black lines are lines fit to the data, or theoretical models. Panel A shows a
theoretical model of abundance of M0 changes with increasing Deuterium available for the synthesis of
this protein. 0 represents M0 with no extra deuterium. Panel B shows how the amount of deuterium
present in the body changes over time. The equations of Panel A and Panel B are combined in such a
way that the resulting equation’s only unknown variable is the protein turnover rate. The actual changes
in M0 are fit to this equation in Panel C, and the turnover rate can be calculated from a variable in the fit
line. The equation is represented in Panel D. The amount of body water enrichment is calculated from
the time based on whatever function is used to fit the water in panel B (first equation). This enrichment is
then used to determine the maximal change in the neutromer peak (middle equation). This can be m0 as
in Panel A, though any neutromer abundance or spacing model will work. The change in Signal
(abundance or spacing) is then represented by the lowest equation, with the k in the equation represents
the peptide turnover rate (bottom equation). This can be solved as an ordinary differential equation in a
least squares curve fit to solve for k.
In this study, we build upon DeuteRater1, our data analysis tool for performing kinetic
proteomics on the simpler labeling scheme, and previous software that uses differential equations
for human kinetic proteomics2 to create DeuteRater-H, an open source software tool to perform
human kinetic proteomic calculations. We show that even in these cases where isotopic
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enrichment is changing neutromer intensity and spacing can be used together to monitor isotope
incorporation and that by incorporating the information from these peptide specific
measurements for each peptide we improve signal to noise in the calculation of protein turnover
kinetics.

4.4 Methods
4.4.1 Metabolic Labeling and Sample Collection
All experiments were performed under the approval of the Institutional Review Board of
Brigham Young University. Three males and three females above the age of 20 years were
recruited. Subjects were randomly assigned numbers from 1-6. Subjects had no serious health
conditions and were not taking regular medication known to cause biases in blood biochemistry,
such as blood thinners. The study lasted for 32 days, divided into 8 day pieces. Each day
subjects consumed 3 doses (morning, noon, and night) of 99.8% deuterated water. The
deuterated water volume was increased following this schedule: 22 mL per dose for the first 24
doses (Day 1-8), 26 mL per dose for the next 24 doses (Days 9-16), 30 mL per dose for the next
24 doses (Day 9-24), and 34 mL per dose for the final 24 doses (Day 25-32). Saliva was
collected daily to allow for measurement of the body water deuterium enrichment. Every 8 days,
subjects were provided with enough doses of deuterated water and saliva sampling swabs
(salivettes) for 3 doses of deuterated water per day and one salivette per day. Subjects kept a
diary to record compliance. Subjects were generally compliant with one or two missed doses
occurring occasionally.
At days 0, 8, 16, 24 and 32, approximately 20 mLs of blood were collected from each
subject. On days 16 and 32 one muscle biopsy from each of the subjects’ legs were collected.
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Biopsies removed approximately 50 mg of tissue per leg. Muscle biopsies were performed by
Dr. Robert Hyldahl at Brigham Young University.
4.4.2 Deviations from the Schedule
Aside from minor non-compliance with a salivette, or deuterium dose, or variations in
amount tissue collected, there were some significant changes to the protocol described above.
Subject 5 started the experiment on schedule but the first blood draw occurred on the day after
deuterium dosing started. Subject 1 had a similar situation, though the first blood draw was 3
days after deuterium was provided. Both of those changes presented minimal issues. More
serious was that Subject 2 started a day after the other subjects, and had an infection at a biopsy
site after the first muscle biopsy. We immediately excluded Subject 2 from further participation
after discovery of the infection.
4.4.3 Measurement of Deuterium Enrichment
Saliva was collected by the subjects and stored frozen until given to researchers. Saliva
was stored by researchers at -20°C until deuterium enrichment could be measured. For
processing, 100 µL aliquots, or less if there were less than 100 µL of saliva, were distilled
overnight at 95° C to purify the water in the sample. 5 µL aliquots of saliva distillates were
diluted 1:300 and deuterium molar percent excess (MPE) was measured. MPE was measured in
the samples against an accompanying standard curve using a cavity ring-down water isotope
analyzer (Los Gatos Research [LGR], Los Gatos, CA, USA) according to the published
method22. Serum was also distilled using the same method (with 50 µL instead of 100) for some
subjects.
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4.4.4 Preparation of Biological Samples
After collection, blood was stored on ice until it could be separated into its components.
First, blood was centrifuged at 200 x g for 20 minutes at 4°C. Serum was removed from red
blood cells and the serum was further centrifuged at 2000 x g for 10 minutes at 4°C. Serum was
removed from buffy coat pellet. The pellet was re-suspended in Phosphate Buffered Saline
(PBS), moved to a storage vial and centrifuged again using the same centrifuge settings. PBS
was decanted. Red blood cells, serum, and buffy coat were stored at -80°C until they could be
processed further. Muscle biopsies were immediately frozen in dry ice. Samples were stored at 0°C.
4.4.5 Preparation for Mass Spectrometry Analysis
Serum protein concentrations were measured using a bicinchoninic acid (BCA) protein
assay (Thermo Fisher). 50 µg of each sample from each subject was placed on 30 kDa mass
cutoff Amicon Ultracel centrifugal filters. 100 µL of guanidine (6 M, 100 mM Tris-HCl pH 8.5)
was added to the sample and centrifuged at 14,000g for 15 minutes. Another wash with
guanidine (same volume and centrifuge settings) was performed. Flow-through was discarded.
100 µL of guanidine was added to the filter, and was brought to 10 mM dithiothreitol. The filter
was placed in a sand bath at 60 °C for 60 minutes. After 5 minutes of cooling, the sample was
brought to 20 mM iodoacetamide. Samples were incubated in the dark for 60 minutes. Samples
were centrifuged at 14,000g for 15 minutes. 200 µL Ammonium Bicarbonate (ABC, 25 mM, pH
8.5) was added to the filters, which were spun at 14,000g for 15 minutes. After a second ABC
wash (same volume and centrifuge settings), ABC was added to the filter until the volume was
300 µL. The collection vial was replaced with a clean vial. 1 µg Trypsin Pierce MS grade was
added to each sample, which were incubated at 37°C overnight. Samples were centrifuged at
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14,000 g for 30 minutes. 100 µL of ABC were added to the filter, which was centrifuged again
for 30 minutes at 14,000 g. Filters were discarded and the filtrate was dried using a SpeedVac
(Sorval) vacuum centrifuge. The dried samples were stored at 4°C until use.
4.4.6 Mass Spectrometry Analysis
All experimental subjects provided five blood samples, all of which were analyzed with a
Fusion Lumos Tribrid (Orbitrap) mass spectrometer from ThermoFisher Scientific. Samples
were resuspended in 0.1% Formic Acid (Pierce LC-MS grade) in H2O (Optima grade Thermo
Fischer). Tryptic peptides were separated using a reverse phase C18 column (Acclaim
PepMap™ 100) and a Thermo Easy-Spray source. Mobile phase for the Liquid Chromatography
was 0.1% Formic Acid in H2O (Buffer A) and 0.1% Formic Acid in 80% Acetonitrile (Optima
grade Thermo Fischer) with 20% H2O (Buffer B) on an Easy-nLC 1200 HPLC system. Samples
were eluted using a gradient of 5% B to 22% B over 85 minutes, 22% to 32% B over 15 minutes,
with a wash of 32% to 95% B over 10 minutes, which was held at 95% B for 10 minutes.
Sample loading and equilibration were performed using the HPLC’s built in methods. MS only
runs were performed using 2400 V in the ion source 60000 Resolution with a scan range of 3751700 m/z, 30% RF Lens, Quadrupole Isolation, 8 *10^5 AGC Target and a maximum injection
time of 50 ms. MS/MS scans were performed using same settings as MS only scans with 3
seconds allowed per MS/MS after each MS scan using the following filters: peptide
monoisotopic peak determination, an intensity threshold of 5*10^3, only fragmenting charge
states +2 to +6, a dynamic exclusion that excluded a peak after being chosen once within 60
seconds, with an error tolerance of 10 ppm high and low, and isotopes excluded. The
fragmentation scan used an isolation window of 1.6 m/z, CID fragmentation with an energy of
30%, detection in the linear ion trap in Rapid scan mode with a AGC target of 1*10^4, a
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maximum injection time of 35 milliseconds and used the “Inject Ions for All Available
Parallelizable Time” option.
Data is available upon request.
4.4.7 Identification of Peptides and Using DeuteRater-H
Peptides were identified from MS/MS spectra of early time point samples using the
software platform PEAKS 823. PEAKS settings were as follows: mass only correct precursor
refinement, trypsin as the digestion enzyme, 3 missed cleavages and 1 non-specific cleavage
allowed. Carbamidomethylation was set as a fixed modification and pyro-glutamic acid from Q
and Oxidation of M were allowed variable modifications with 3 variable modifications allowed
per peptide. Identification database was SwissProt validated database downloaded August 2017,
restricted to Homo sapiens protein entries. PEAKS PTM, which searches for PTMs not specified
in the search, and SPIDER, which searches for point mutations, were also examined. Data from
the Orbitrap instrument was analyzed with settings specifying CID fragmentation, precursor data
was collected in an Orbitrap with an allowed error tolerance of 4.0 ppms, and fragmentation data
was collected in a linear ion trap with an allowed error of 0.2 Daltons. QToF data was analyzed
with settings specifying CID fragmentation, precursor data was collected in a ToF with an error
tolerance of 10.0 ppms , and fragmentation data was collected in a ToF with an allowed error of
0.05 daltons.
Those identifications under a 1% False Discovery Rate cutoff were exported and used to
create a peptide accurate mass and retention time database for DeuteRater. All post-translational
modifications except carbamidomethylation, pyroglutamic acid from Q and oxidation of M were
discarded. High confidence peptide identifications that incorporated point mutations from
SPIDER were kept. Data was then analyzed by DeuteRater-H. Details of DeuteRater-H
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calculation are in the Results section under “Changes made to DeuteRater for Human
Calculations”.
4.4.8 Filtering Turnover Rate Results
All protein turnover rates were calculated by averaging the rates of peptide measurements
(abundance and spacing of all neutromers) from peptides belonging to that protein that had rate
fits with an R2 value greater than or equal to 0.9 and a coefficient of variance (standard deviation
/ rate value) (cv) of 0.5 or less. Several filters were applied to protein rates: to ensure that these
average rates were within the reliable range defined by our sampling, all rates below 0 or above 2
(fractional turnover per day) were removed, all protein rates coming from a single measurement
were removed. The cv filter was designed to ensure that when filtering by error, the
measurement was not biased against faster rates whose 95% confidence intervals have higher
numerical values even if the relative error is quite small.
4.4.9 Comparison of Kinetic Rates to Kinetic Rates from Previous Studies
For comparison between subjects, all proteins present in all 6 subjects that made it
through the filter described in “Filtering Turnover Rate Results” were transformed (log base 2)
and subjected to a Tukey Kramer comparison of multiple means by the JMP 12 statistical
software package.
For comparison between our data and published data, we averaged all proteins that made
it through the filter described in “Filtering Turnover Rate Results” were averaged across all
experimental subjects. Rates reported from the literature were averaged across all subjects in the
study they appeared in and those rates not between 0 and 2 (fractional turnover per day) were
removed.
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4.5 Results
4.5.1 Changes made to DeuteRater for Human Calculations
Starting from the framework of DeuteRater1, we made two major changes. First, we
required the user to provide data on heavy isotope enrichment at various time-points for each
experimental subject. After collecting this data, we created a fit line for that data with an
equation chosen by the user (rise to plateau by default). Second, differential rate calculations
(Figure 4-3) were performed on a peptide by peptide basis, unlike in DeuteRater. Rates with an
R2 of greater than 0.9 and a coefficient of variance (cv) (calculated as standard deviation / rate
value) of less than 0.5 were kept (by default, filters can be altered), other rates were discarded.
Rates for peptides belonging to the same protein were weighted by cv and averaged together to
obtain a turnover rate for the protein. Peptides and proteins were calculated independently for
each experimental subject.
4.5.2 Improved Flexibility of DeuteRater-H
In previous studies of human kinetic proteomics, a rise to plateau model has been used
for the deuterium enrichment of experimental subjects2,3. This was a reasonable way to start the
method as it most closely models the small animal calculations, and it is experimentally easier,
requiring the experimental subjects to consume the same volume of deuterium on the same
schedule for the entire experiment. Since DeuteRater-H uses a differential equation and should
be able to use any shape of enrichment profile (Figure 4-3 D), we provided subjects with
increasing amount of deuterium throughout the experiment as detailed under “Metabolic
Labeling and Sample Collection” in the Methods section. We did this to provide flexibility to
the calculations, and to test whether the increasing amount of deuterium would allow
measurements of fast turnover proteins at late time points to be useful in calculating the turnover
92

rate, as observed previously3. The increasing deuterium amounts do not cause any noticeable
negative results to the subjects or the data analysis.
Previous work also focused on the abundance change of the mono-isotopic peak2. The
mono-isotopic peak is often the best peak for kinetic calculations because its intensity change is
usually relatively large and is easily predictable. However, we established with DeuteRater1 that
multiple changes in the isotope pattern, including the spacing between neutromers, can be used
to improve the quality of the kinetic calculations. In DeuteRater-H we have demonstrated that
all measurements can also be utilized in a situation where isotopic enrichment is changing over
time (Figure 4-4). However, not all measurements are useful for every peptide. Some metrics,
especially spacing, have low signal to noise. As a result, DeuteRater-H applies filters to the
peptide rate calculated from each metric. Only those calculated curves with an R2 greater than
0.9, and a coefficient of variation less than 0.5 were rolled into protein rates.
4.5.3 Comparison of Experimental Subjects to Each Other
Experimental subjects were compared to each other to ensure that analysis of healthy
subjects yields similar results. If the subjects were vastly different from each other, it could
indicate a problem with the software performing the calculations. A Tukey-Kramer multiple
comparison test was used to compare all turnover rates from all proteins in the filtered data that
were present in all 6 experimental subjects with at least two peptide calculations, either two or
more peptides for a single protein or two or more abundance or spacing metrics passing the
filters for a single peptide (Table 4-1). Turnover rates underwent a Logarithmic transformation
(base 2) prior to statistical testing to create a normal distribution. Turnover rates represented in
Table 4-1 are not transformed. Logarithmic transformation of data and the Tukey-Kramer test,
which compares all possible combinations of subjects, were performed using the JMP 12
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statistical package. The result showed four significant differences, between Subject 2 and
Subject 1, Subject 2 and Subject 4, Subject 2 and Subject 5, and Subject 2 and Subject 6 with pvalues of .0390, .0452, .0473, and .0476 respectively.

Figure 4-4 Improved Calculations using DeuteRater-H. Panel A shows a deuterium enrichment curve
for Subject 5 in this study. Panel B shows the metrics used in fitting, the ΔI values indicating abundance
changes, and the Δ M –M0 measurements indicating differences in spacing which were discussed in depth
in Figure 4-3 and our previous work. DeuteRater-H allows calculation of human turnover rates by
combining multiple metrics including the traditional M0 peak (no heavy isotopes panel C), other isotopic
peaks (D-E) and the spacing between peaks (F). Panels C-F are for peptide ADLSGITGAR from subject
5. All time-points have two measurements at each time point (representing charge states +2 and +3)
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All significant differences are between Subject 2 and other subjects. Subject 2 had health
problems due to a leg infection as a result of the muscle biopsy, and had a drop in enrichment
around week 3 due to strenuous exercise. Therefore, the significantly decreased rates in for
Subject 2 may be due to exertion changing water consumption and reducing deuterium
enrichment, or may be some biological effect from the exertion or infection.
Table 4-1 Data from Proteins in All Six Experimental Subjects. This table shows the accession numbers
and turnover rates of proteins observed in all 6 subjects with more than one measurement (peptide,
abundance measurement, or spacing measurement). The turnover units are fractional turnover per day
with error being 2 standard deviations to approximate a 95% confidence interval.

Protein
Accession
Number

Protein Name

P0DOY3

Immunoglobulin lambda 0.04 ± 0.03 ± 0.03 ± 0.09 ± 0.04 ± 0.04 ±
constant 3
0.002 0.004 0.027 0.044 0.065 0.006

P0DOX8

Immunoglobulin
lambda-1 light chain

0.05 ± 0.1 ±
0.043 0.06

A0A075B6P5

Immunoglobulin kappa
variable 2-28

0.13 ± 0.03 ± 0.03 ± 0.06 ± 0.01 ± 0.04 ±
0.107 0.03
0.008 0.051 0.005 0.015

P02746

Complement C1q
0.13 ± 0.15 ± 0.1 ±
subcomponent subunit B 0.046 0.085 0.163

P35542

Serum amyloid A-4
protein

0.12 ± 0.11 ± 0.16 ± 0.07 ± 0.14 ± 0.16 ±
0.026 0.189 0.006 0.223 0.122 0.023

P01619

Immunoglobulin kappa
variable 3-20

0.08 ± 0.08 ± 0.04 ± 0.06 ± 0.02 ± 0.04 ±
0.095 0.028 0.142 0.072 0.03
0.023

P0DOX7

Immunoglobulin kappa
light chain

0.08 ± 0.03 ± 0.03 ± 0.04 ± 0.02 ± 0.04 ±
0.088 0.047 0.115 0.041 0.107 0.027

P01871

Immunoglobulin heavy
constant mu

0.15 ± 0.08 ± 0.05 ± 0.07 ± 0.06 ± 0.05 ±
0.113 0.039 0.048 0.051 0.072 0.027

A0A0C4DH31 Immunoglobulin heavy
variable 1-18

0.12 ± 0.03 ± 0.03 ± 0.08 ± 0.05 ± 0.03 ±
0.062 0.021 0.025 0.044 0.141 0.036

O14791

0.13 ± 0.08 ± 0.1 ±
0.021 0.066 0.071

Apolipoprotein L1

S1
Rate

95

S2
Rate

S3
Rate

S4
Rate

S5
Rate

S6
Rate

0.03 ± 0.07 ± 0.02 ± 0.04 ±
0.019 0.048 0.004 0.013

0.23 ± 0.18 ± 0.2 ±
0.193 0.167 0.017

0.15 ± 0.14 ± 0.1 ±
0.124 0.136 0.036

Protein
Accession
Number

Protein Name

P0DOX2

Immunoglobulin alpha-2 0.11 ± 0.07 ± 0.08 ± 0.09 ± 0.03 ± 0.05 ±
heavy chain
0.257 0.046 0.126 0.068 0.062 0.039

P00739

Haptoglobin-related
protein

0.14 ± 0.07 ± 0.08 ± 0.1 ±
0.031 0.012 0.014 0.057

P05090

Apolipoprotein D

0.1 ±
0.043

P02768

Serum albumin

0.04 ± 0.03 ± 0.03 ± 0.07 ± 0.03 ± 0.03 ±
0.078 0.026 0.045 0.049 0.049 0.048

P01701

Immunoglobulin lambda 0.03 ± 0.03 ± 0.04 ± 0.07 ± 0.03 ± 0.06 ±
variable 1-51
0.002 0.014 0.019 0.088 0.002 0.05

P01023

Alpha-2-macroglobulin

0.07 ± 0.07 ± 0.05 ± 0.15 ± 0.06 ± 0.06 ±
0.05
0.025 0.084 0.063 0.067 0.051

P01876

Immunoglobulin heavy
constant alpha 1

0.06 ± 0.05 ± 0.08 ± 0.21 ± 0.08 ± 0.08 ±
0.062 0.044 0.154 0.092 0.086 0.054

P0DOX5

Immunoglobulin
gamma-1 heavy chain

0.1 ±
0.073

P02790

Hemopexin

0.11 ± 0.08 ± 0.07 ± 0.21 ± 0.07 ± 0.07 ±
0.203 0.034 0.114 0.117 0.073 0.062

P02787

Serotransferrin

0.1 ±
0.074

0.09 ± 0.08 ± 0.13 ± 0.09 ± 0.07 ±
0.088 0.098 0.101 0.078 0.073

P08185

Corticosteroid-binding
globulin

0.1 ±
0.052

0.06 ± 0.08 ± 0.07 ± 0.15 ± 0.08 ±
0.039 0.096 0.162 0.102 0.076

P43652

Afamin

0.12 ± 0.07 ± 0.15 ± 0.11 ± 0.16 ± 0.15 ±
0.085 0.115 0.29
0.146 0.108 0.084

P00450

Ceruloplasmin

0.13 ± 0.07 ± 0.11 ± 0.11 ± 0.12 ± 0.12 ±
0.141 0.108 0.117 0.166 0.084 0.086

P02652

Apolipoprotein A-II

0.2 ±
0.059

P27169

Serum
0.29 ± 0.1 ±
paraoxonase/arylesterase 0.143 0.061
1

S1
Rate
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S2
Rate

S3
Rate

S4
Rate

S5
Rate

0.1 ±
0.029

S6
Rate

0.1 ±
0.039

0.04 ± 0.09 ± 0.09 ± 0.11 ± 0.09 ±
0.004 0.078 0.057 0.155 0.043

0.03 ± 0.03 ± 0.07 ± 0.02 ± 0.03 ±
0.025 0.08
0.052 0.045 0.056

0.12 ± 0.16 ± 0.22 ± 0.17 ± 0.14 ±
0.16
0.205 0.239 0.252 0.09
0.09 ± 0.19 ± 0.15 ± 0.1 ±
0.065 0.161 0.112 0.099

Protein
Accession
Number

Protein Name

S1
Rate

P02763

Alpha-1-acid
glycoprotein 1

0.31 ± 0.12 ± 0.13 ± 0.38 ± 0.14 ± 0.14 ±
0.25
0.089 0.165 0.223 0.125 0.101

P01009

Alpha-1-antitrypsin

0.11 ± 0.07 ± 0.13 ± 0.12 ± 0.15 ± 0.13 ±
0.148 0.076 0.162 0.145 0.13
0.121

P02766

Transthyretin

0.09 ± 0.2 ±
0.031 0.273

P02765

Alpha-2-HSglycoprotein

0.09 ± 0.11 ± 0.14 ± 0.05 ± 0.17 ± 0.15 ±
0.134 0.062 0.135 0.178 0.163 0.13

P02647

Apolipoprotein A-I

0.14 ± 0.07 ± 0.13 ± 0.13 ± 0.17 ± 0.12 ±
0.071 0.057 0.102 0.196 0.112 0.133

P02760

Protein AMBP

0.12 ± 0.08 ± 0.15 ± 0.32 ± 0.17 ± 0.26 ±
0.239 0.18
0.198 0.279 0.285 0.134

P01011

Alpha-1antichymotrypsin

0.18 ± 0.09 ± 0.16 ± 0.19 ± 0.16 ± 0.11 ±
0.185 0.198 0.281 0.283 0.165 0.136

P15169

Carboxypeptidase N
catalytic chain

0.2 ±
0.145

P06396

Gelsolin

0.12 ± 0.19 ± 0.13 ± 0.15 ± 0.17 ± 0.14 ±
0.188 0.138 0.182 0.259 0.162 0.147

P00734

Prothrombin

0.23 ± 0.13 ± 0.18 ± 0.18 ± 0.24 ± 0.18 ±
0.216 0.136 0.199 0.16
0.159 0.15

P02679

Fibrinogen gamma
chain

0.17 ± 0.08 ± 0.13 ± 0.21 ± 0.16 ± 0.18 ±
0.237 0.185 0.134 0.178 0.148 0.156

P19827

Inter-alpha-trypsin
0.16 ± 0.17 ± 0.2 ±
inhibitor heavy chain H1 0.169 0.157 0.237

P02675

Fibrinogen beta chain

0.15 ± 0.08 ± 1.34 ± 0.45 ± 0.18 ± 0.19 ±
0.182 0.089 0.218 0.175 0.175 0.158

P06727

Apolipoprotein A-IV

0.1 ±
0.13

P04003

C4b-binding protein
alpha chain

0.13 ± 0.08 ± 0.13 ± 0.14 ± 0.19 ± 0.13 ±
0.286 0.09
0.135 0.162 0.14
0.178
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S2
Rate

S3
Rate

0.2 ±
0.255

S4
Rate

S5
Rate

0.18 ± 0.3 ±
0.331 0.351

S6
Rate

0.27 ±
0.122

0.08 ± 0.11 ± 0.17 ± 0.14 ± 0.16 ±
0.013 0.077 0.116 0.111 0.139

0.21 ± 0.22 ± 0.23 ±
0.237 0.193 0.156

0.16 ± 0.11 ± 0.1 ±
0.25
0.082 0.13

0.17 ± 0.12 ±
0.129 0.169

Protein
Accession
Number

Protein Name

S1
Rate

P01042

Kininogen-1

0.17 ± 0.14 ± 0.18 ± 0.26 ± 0.21 ± 0.17 ±
0.248 0.123 0.181 0.235 0.2
0.181

P02748

Complement component
C9

0.11 ± 0.38 ± 0.15 ± 0.19 ± 0.3 ±
0.141 0.429 0.14
0.147 0.296

P08603

Complement factor H

0.13 ± 0.08 ± 0.13 ± 0.3 ±
0.112 0.079 0.146 0.142

P10643

Complement component
C7

0.12 ± 0.09 ± 0.15 ± 0.15 ± 0.1 ±
0.095 0.038 0.134 0.092 0.225

P04217

Alpha-1B-glycoprotein

0.25 ± 0.17 ± 0.16 ± 0.23 ± 0.23 ± 0.2 ±
0.246 0.149 0.161 0.282 0.176 0.189

P08697

Alpha-2-antiplasmin

0.21 ± 0.17 ± 0.22 ± 0.14 ± 0.27 ± 0.31 ±
0.351 0.331 0.432 0.19
0.368 0.192

P01024

Complement C3

0.15 ± 0.17 ± 0.2 ±
0.257 0.21
0.247

P02774

Vitamin D-binding
protein

0.16 ± 0.38 ± 0.25 ± 0.05 ± 0.24 ± 0.24 ±
0.246 0.246 0.308 0.277 0.243 0.222

P36955

Pigment epitheliumderived factor

0.14 ± 0.14 ± 0.19 ± 0.09 ± 0.37 ± 0.22 ±
0.087 0.06
0.258 0.153 0.169 0.235

P01019

Angiotensinogen

0.08 ± 0.31 ± 0.21 ± 0.23 ± 0.27 ± 0.23 ±
0.154 0.247 0.523 0.258 0.207 0.24

Q14624

Inter-alpha-trypsin
0.18 ± 0.33 ± 0.22 ± 0.2 ±
inhibitor heavy chain H4 0.166 0.238 0.332 0.205

P01008

Antithrombin-III

0.33 ± 0.18 ± 0.21 ± 0.18 ± 0.27 ± 0.22 ±
0.288 0.158 0.301 0.299 0.273 0.268

P04196

Histidine-rich
glycoprotein

0.38 ± 0.3 ±
0.271 0.234

P02671

Fibrinogen alpha chain

0.16 ± 0.09 ± 0.17 ± 0.23 ± 0.21 ± 0.45 ±
0.245 0.172 0.217 0.239 0.212 0.287

P00747

Plasminogen

0.46 ± 0.38 ± 0.23 ± 0.13 ± 0.26 ± 0.24 ±
0.325 0.214 0.291 0.265 0.273 0.289
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S2
Rate

S3
Rate

S4
Rate

S5
Rate

S6
Rate

0.25 ±
0.184

0.17 ± 0.14 ±
0.147 0.185
0.14 ±
0.187

0.22 ± 0.23 ± 0.2 ±
0.238 0.193 0.199

0.28 ± 0.22 ±
0.218 0.258

0.21 ± 0.22 ± 0.23 ± 0.35 ±
0.369 0.262 0.213 0.282

Protein
Accession
Number

Protein Name

S1
Rate

P01031

Complement C5

0.12 ± 0.08 ± 0.18 ± 0.08 ± 0.21 ± 0.23 ±
0.115 0.031 0.229 0.176 0.2
0.297

P05543

Thyroxine-binding
globulin

0.2 ±
0.241

0.06 ± 0.13 ± 0.23 ± 0.16 ± 0.14 ±
0.043 0.082 0.136 0.119 0.297

P06312

Immunoglobulin kappa
variable 4-1

0.6 ±
0.347

0.03 ± 0.16 ± 0.04 ± 0.03 ± 0.07 ±
0.011 0.49
0.064 0.008 0.305

P19823

Inter-alpha-trypsin
0.12 ± 0.29 ± 0.21 ± 0.18 ± 0.26 ± 0.21 ±
inhibitor heavy chain H2 0.23
0.211 0.236 0.229 0.21
0.308

P05155

Plasma protease C1
inhibitor

0.15 ± 0.07 ± 0.3 ±
0.047 0.011 0.463

P00738

Haptoglobin

0.14 ± 0.07 ± 0.34 ± 0.14 ± 0.27 ± 0.31 ±
0.27
0.244 0.469 0.162 0.239 0.334

P02751

Fibronectin

0.19 ± 0.1 ±
0.086 0.331

P00751

Complement factor B

0.24 ± 0.06 ± 0.25 ± 0.16 ± 0.26 ± 0.27 ±
0.239 0.296 0.313 0.218 0.309 0.335

P04004

Vitronectin

0.37 ± 0.13 ± 0.27 ± 0.27 ± 0.32 ± 0.3 ±
0.264 0.201 0.297 0.26
0.295 0.375

P04114

Apolipoprotein B-100

0.08 ± 0.17 ± 0.22 ± 0.1 ±
0.285 0.311 0.286 0.226

P02749

Beta-2-glycoprotein 1

0.15 ± 0.08 ± 0.42 ± 0.23 ± 0.46 ± 0.39 ±
0.24
0.22
0.547 0.288 0.382 0.393

P07225

Vitamin K-dependent
protein S

0.12 ± 0.11 ± 0.14 ± 0.14 ± 0.14 ± 0.14 ±
0.047 0.069 0.135 0.253 0.149 0.401

P13671

Complement component
C6

0.46 ± 0.15 ± 0.2 ±
0.061 0.169 0.509

P10909

Clusterin

0.38 ± 0.4 ±
0.229 0.28

P02649

Apolipoprotein E

0.19 ± 0.22 ± 0.39 ± 0.38 ± 0.57 ± 0.41 ±
0.279 0.307 0.506 0.306 0.508 0.445
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S2
Rate

S3
Rate

S4
Rate

0.1 ±
0.035

0.28 ± 0.2 ±
0.352 0.242

S5
Rate

S6
Rate

0.36 ± 0.27 ±
0.36
0.327

0.23 ± 0.32 ±
0.292 0.334

0.24 ± 0.25 ±
0.321 0.387

0.15 ± 0.28 ± 0.26 ±
0.163 0.275 0.407

0.24 ± 0.21 ± 0.39 ± 0.29 ±
0.301 0.322 0.617 0.441

Figure 4-5 Comparison of DeuteRater-H to Previous Human Kinetic Proteomics Experiments. This

figure compares turnover rates of proteins observed in humans. Points are turnover rates of the same
protein in the different studies. The solid black lines represent the unity line, where all points should be
assuming no error. The dotted black line and equations represent the best fit line of the comparison.
Panel A shows a comparison to Lam et al upon which we based our differential calculations1-4, while
panel B shows a comparison to a study that used SAAM II compartmental models5,6. Panel C shows
comparison of Price et al and Lam et al to determine the expected amount of error due to biological
noise. Fits are Passing-Bablok regressions to prevent problems due to outliers.

4.5.4 Comparison to Previous Work
The final test of new software is validation of turnover rates using previously published
datasets. Since all previous studies and the current study contained multiple non-genetically
identical subjects, we averaged all calculated protein rates across all subjects for which it was
observed in both our dataset, previous explicit differential calculations2 or SAAM II
compartmental models3. All data points used in this comparison are shown in Table 4-2. We
then compared all proteins calculated by the current study to the other studies (Figure 4-5).
Agreement is sufficiently good to justify publication.
Table 4-2 Data points used in Figure 4-5. If a cell contains “N.O.” it was not observed in that study,
and so not graphed. Values are rates average rates between all samples ± std. dev. A std. dev. of 0
indicates a rate was only observed for one subject in that study, so no std. dev. could be calculated.

Protein
Protein Number
Accession
Number

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P01834

0.05±0.015

0.03±0.015

0.02±0.001

Immunoglobulin kappa constant

100

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P01859

Immunoglobulin heavy constant gamma
2

0.05±0.020

0.04±0.006

0.02±0.005

P0DOX5

Immunoglobulin gamma-1 heavy chain

0.06±0.018

N.O.

0.01±0.004

P0DOY3

Immunoglobulin lambda constant 3

0.06±0.030

N.O.

0.02±0.001

P0DOX7

Immunoglobulin kappa light chain

0.06±0.027

N.O.

0.03±0.006

P0DOX8

Immunoglobulin lambda-1 light chain

0.06±0.022

N.O.

0.03±0.002

P01861

Immunoglobulin heavy constant gamma
4

0.07±0

0.04±0.015

0.01±0.003

P04433

Immunoglobulin kappa variable 3-11

0.07±0.008

0.02±0

0.02±0.007

P02745

Complement C1q subcomponent subunit
A

0.07±0.026

0.13±0.030

0.18±0.025

P02768

Serum albumin

0.07±0.021

0.03±0.019

0.03±0.030

P01023

Alpha-2-macroglobulin

0.08±0.012

0.04±0.008

0.04±0.011

P80748

Immunoglobulin lambda variable 3-21

0.08±0.005

0.00±0

0.02±0

P01871

Immunoglobulin heavy constant mu

0.09±0.031

0.04±0.026

0.11±0.090

A0A075B
6P5
Immunoglobulin kappa variable 2-28

0.09±0.033

N.O.

0.03±0.003

P01619

Immunoglobulin kappa variable 3-20

0.09±0.023

N.O.

0.03±0

P00739

Haptoglobin-related protein

0.10±0.014

2.84±2.610

0.32±0.046

Protein
Protein Number
Accession
Number
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Protein
Protein Number
Accession
Number

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P02787

Serotransferrin

0.10±0.012

0.08±0.026

0.05±0.024

P02747

Complement C1q subcomponent subunit
C

0.10±0.015

0.10±0.007

0.17±0.092

P02790

Hemopexin

0.11±0.032

0.06±0.000

0.11±0.068

P01876

Immunoglobulin heavy constant alpha 1

0.12±0.024

0.08±0.019

0.06±0.011

P08185

Corticosteroid-binding globulin

0.12±0.047

0.08±0.003

0.22±0.179

P01860

Immunoglobulin heavy constant gamma
3

0.13±0.016

0.08±0.023

0.01±0

P00450

Ceruloplasmin

0.13±0.012

0.10±0.026

0.11±0.055

P19652

Alpha-1-acid glycoprotein 2

0.14±0.014

0.17±0.027

0.14±0.056

P02746

Complement C1q subcomponent subunit
B

0.14±0.049

0.09±0.019

0.18±0

P02750

Leucine-rich alpha-2-glycoprotein

0.15±0.050

0.18±0.040

0.19±0.049

O75636

Ficolin-3

0.15±0.038

0.15±0.035

0.18±0

P00748

Coagulation factor XII

0.16±0.066

0.21±0.031

0.27±0.091

P29622

Kallistatin

0.16±0.056

0.23±0.077

0.38±0.138

P01009

Alpha-1-antitrypsin

0.17±0.019

0.09±0.019

0.12±0.054

P08603

Complement factor H

0.18±0.028

0.14±0.036

0.16±0.056
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Protein
Protein Number
Accession
Number

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P49908

Selenoprotein P

0.19±0

0.81±0.429

0.58±0

P02652

Apolipoprotein A-II

0.20±0.045

0.15±0.058

0.21±0.102

P02679

Fibrinogen gamma chain

0.20±0.027

0.13±0.041

0.16±0.078

P02765

Alpha-2-HS-glycoprotein

0.21±0.101

0.15±0.031

0.19±0.070

P02675

Fibrinogen beta chain

0.21±0.022

0.09±0.030

0.14±0.058

P05546

Heparin cofactor 2

0.21±0.088

0.26±0.048

0.23±0.055

P06727

Apolipoprotein A-IV

0.22±0.081

0.31±0.072

0.64±0.315

Q9NZP8

Complement C1r subcomponent-like
protein

0.22±0

0.32±0.062

0.73±0

P01011

Alpha-1-antichymotrypsin

0.23±0.082

0.14±0.019

0.19±0.169

Q96PD5

N-acetylmuramoyl-L-alanine amidase

0.23±0.039

0.20±0.046

0.20±0.035

P02760

Protein AMBP

0.23±0.072

0.40±0.222

0.38±0.120

P04217

Alpha-1B-glycoprotein

0.24±0.025

0.18±0.022

0.24±0.102

P19827

Inter-alpha-trypsin inhibitor heavy chain
H1

0.24±0.034

0.19±0.022

0.37±0.224

P00734

Prothrombin

0.25±0.058

0.22±0.034

0.24±0.098

P00742

Coagulation factor X

0.25±0.158

0.29±0.035

0.46±0
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Protein Number
Accession
Number

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P02671

Fibrinogen alpha chain

0.26±0.033

0.16±0.028

0.17±0.074

P07360

Complement component C8 gamma
chain

0.26±0.066

0.20±0.025

0.26±0

P19823

Inter-alpha-trypsin inhibitor heavy chain
H2

0.26±0.032

0.20±0.046

0.29±0.109

P01019

Angiotensinogen

0.26±0.113

0.26±0.061

0.32±0.148

P01042

Kininogen-1

0.27±0.039

0.33±0.129

0.26±0.093

P35858

Insulin-like growth factor-binding
protein complex acid labile subunit

0.27±0.146

0.24±0.031

0.54±0.246

P06681

Complement C2

0.27±0.078

0.33±0.069

0.38±0

P25311

Zinc-alpha-2-glycoprotein

0.27±0.105

0.25±0.082

0.37±0.087

P05543

Thyroxine-binding globulin

0.28±0.152

0.10±0.022

0.24±0

P01031

Complement C5

0.28±0.111

0.19±0.031

0.29±0.148

P22792

Carboxypeptidase N subunit 2

0.28±0.245

0.20±0.049

0.28±0

P02763

Alpha-1-acid glycoprotein 1

0.29±0.204

0.19±0.100

0.14±0.051

P01024

Complement C3

0.30±0.083

0.17±0.027

0.27±0.099

P02774

Vitamin D-binding protein

0.31±0.051

0.36±0.126

0.34±0.153

P05156

Complement factor I

0.31±0.026

0.32±0.071

0.21±0
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Protein Number
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Number

DeuteRaterH Rate

Lam et al2
Rate

Price et al3
Rate

P00751

Complement factor B

0.32±0.071

0.26±0.030

0.33±0.156

P02766

Transthyretin

0.33±0.257

0.25±0.043

0.31±0.267

P07358

Complement component C8 beta chain

0.33±0.175

0.23±0.028

0.25±0.149

P02748

Complement component C9

0.33±0.250

0.25±0.017

0.30±0.088

P06312

Immunoglobulin kappa variable 4-1

0.33±0.213

N.O.

0.02±0.008

P0C0L5

Complement C4-B

0.33±0.070

0.30±0.060

0.32±0.123

P08697

Alpha-2-antiplasmin

0.34±0.089

0.21±0.073

0.19±0.103

P04196

Histidine-rich glycoprotein

0.35±0.128

0.26±0.055

0.37±0.049

P00738

Haptoglobin

0.35±0.126

0.35±0.122

0.46±0.552

P01008

Antithrombin-III

0.37±0.094

0.23±0.054

0.40±0.156

Q14624

Inter-alpha-trypsin inhibitor heavy chain
H4

0.39±0.291

0.22±0.040

0.44±0.161

P06396

Gelsolin

0.40±0.397

0.19±0.024

0.23±0.029

P0C0L4

Complement C4-A

0.40±0.170

0.43±0.035

0.28±0.085

P00747

Plasminogen

0.41±0.119

0.30±0.056

0.36±0.131

P13671

Complement component C6

0.41±0.100

0.39±0.061

0.26±0.092
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Number

DeuteRaterH Rate
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Rate

Price et al3
Rate

P05155

Plasma protease C1 inhibitor

0.48±0.289

0.28±0.067

0.27±0.068

P36955

Pigment epithelium-derived factor

0.50±0.562

0.21±0.033

0.47±0.015

P04004

Vitronectin

0.51±0.261

0.47±0.120

0.73±0.162

P27169

Serum paraoxonase/arylesterase 1

0.53±0.627

0.08±0.028

0.05±0

P02751

Fibronectin

0.53±0.349

0.15±0.053

0.45±0.171

P09871

Complement C1s subcomponent

0.54±0.376

0.74±0.258

0.39±0.142

P02656

Apolipoprotein C-III

0.60±0.334

0.47±0.093

0.79±0.120

P43652

Afamin

0.60±0.506

0.14±0.036

0.21±0.067

P00736

Complement C1r subcomponent

0.63±0.747

0.71±0.244

0.69±0.248

P02749

Beta-2-glycoprotein 1

0.64±0.325

0.54±0.125

0.56±0.221

P02753

Retinol-binding protein 4

0.72±0.690

1.19±0.161

0.96±0

P10909

Clusterin

0.73±0.762

0.48±0.089

0.90±0.475

P02649

Apolipoprotein E

0.76±0.489

0.75±0.162

1.00±0.525

P13645

Keratin type I cytoskeletal 10

0.06±0

0.00±0.006

N.O.

P20742

Pregnancy zone protein

0.08±0

0.01±0.01

N.O.
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DeuteRaterH Rate
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Rate

Price et al3
Rate

P05090

Apolipoprotein D

0.11±0.047

0.04±0.002

N.O.

O75882

Attractin

0.07±0.046

0.04±0.014

N.O.

P04180

Phosphatidylcholine-sterol
acyltransferase

0.10±0.003

0.05±0

N.O.

Q15582

Transforming growth factor-betainduced protein ig-h3

0.10±0

0.05±0.002

N.O.

Q15848

Adiponectin

0.07±0

0.05±0.012

N.O.

P06276

Cholinesterase

0.17±0

0.05±0.010

N.O.

P20851

C4b-binding protein beta chain

0.16±0.049

0.08±0

N.O.

P14151

L-selectin

0.08±0

0.08±0.010

N.O.

P22352

Glutathione peroxidase 3

0.10±0.028

0.08±0.034

N.O.

O43866

CD5 antigen-like

0.11±0.029

0.09±0.052

N.O.

P08519

Apolipoprotein(a)

0.33±0.200

0.09±0

N.O.

P15169

Carboxypeptidase N catalytic chain

0.16±0.036

0.09±0.009

N.O.

P05452

Tetranectin

0.10±0.006

0.10±0.016

N.O.

P01591

Immunoglobulin J chain

0.15±0.126

0.11±0

N.O.

Q16610

Extracellular matrix protein 1

0.16±0.049

0.12±0.032

N.O.
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DeuteRaterH Rate
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Rate

Price et al3
Rate

P43251

Biotinidase

0.09±0

0.13±0.024

N.O.

P02647

Apolipoprotein A-I

0.16±0.029

0.14±0.061

N.O.

P04003

C4b-binding protein alpha chain

0.18±0.033

0.14±0.031

N.O.

P23142

Fibulin-1

0.12±0.018

0.16±0.032

N.O.

P03952

Plasma kallikrein

0.23±0.067

0.16±0.052

N.O.

P35542

Serum amyloid A-4 protein

0.16±0.026

0.16±0.052

N.O.

P07225

Vitamin K-dependent protein S

0.26±0.131

0.17±0.025

N.O.

P10643

Complement component C7

0.20±0.087

0.19±0.029

N.O.

Q04756

Hepatocyte growth factor activator

0.24±0.076

0.19±0.032

N.O.

P05160

Coagulation factor XIII B chain

0.27±0.071

0.23±0.086

N.O.

Q13790

Apolipoprotein F

0.16±0

0.23±0.037

N.O.

Q96KN2

Beta-Ala-His dipeptidase

0.08±0

0.24±0.038

N.O.

Q03591

Complement factor H-related protein 1

0.34±0.105

0.26±0

N.O.

P48740

Mannan-binding lectin serine protease 1

0.28±0

0.27±0.065

N.O.

P07357

Complement component C8 alpha chain

0.46±0.443

0.28±0.062

N.O.
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Price et al3
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P04114

Apolipoprotein B-100

0.48±0.268

0.28±0.064

N.O.

Q9UGM5

Fetuin-B

0.27±0.159

0.31±0.110

N.O.

Q06033

Inter-alpha-trypsin inhibitor heavy chain
H3

0.36±0.130

0.32±0.053

N.O.

P18428

Lipopolysaccharide-binding protein

0.33±0

0.33±0.107

N.O.

Q96IY4

Carboxypeptidase B2

0.19±0

0.33±0.047

N.O.

P17936

Insulin-like growth factor-binding
protein 3

0.10±0

0.34±0.100

N.O.

P02743

Serum amyloid P-component

0.29±0.099

0.39±0.156

N.O.

P55056

Apolipoprotein C-IV

0.16±0

0.39±0.053

N.O.

Q08380

Galectin-3-binding protein

0.15±0.083

0.45±0.233

N.O.

Q14520

Hyaluronan-binding protein 2

1.74±2.668

0.46±0.116

N.O.

P02654

Apolipoprotein C-I

0.68±0.176

0.48±0.226

N.O.

Q9UK55

Protein Z-dependent protease inhibitor

0.05±0

0.49±0.117

N.O.

P02655

Apolipoprotein C-II

0.20±0

0.55±0.179

N.O.

P00740

Coagulation factor IX

0.17±0.032

0.56±0.172

N.O.

Q5D862

Filaggrin-2

0.08±0

0.64±0

N.O.
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P36980

Complement factor H-related protein 2

0.64±0.682

1.08±1.025

N.O.

O95445

Apolipoprotein M

0.41±0.330

1.33±0

N.O.

O14791

Apolipoprotein L1

0.13±0.026

1.42±1.277

N.O.

4.6 Discussion
We created DeuteRater-H, a version of DeuteRater adjusted for human kinetic
proteomics. The program calculates protein turnover rates on a proteome scale. We have
enabled the use of multiple equations for deuterium enrichment fits, and have enabled the
calculation of protein turnover rates from multiple metrics in humans, as we have previously
done for our DeuteRater software tool1. The program is free to use, user-friendly and can
calculate large numbers of protein turnover rates at a time.
However, there are still problems to address before DeuteRater-H is ready for release.
The main problem is justifying then novel nature of DeuteRater-H as an improvement on
previously published methods. Work is ongoing to demonstrate that the use of multiple metrics
are useful in kinetic calculations.

4.7 Future Directions
4.7.1 Computational Development
The main changes that need to be made to DeuteRater-H are more comparisons to
confirm that multiple metrics are useful. I will also create an executable file to make it easier for
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other labs to use DeuteRater-H. As soon as these steps are accomplished, DeuteRater-H will be
ready for distribution.
4.7.2 Biology
Once the DeuteRater-H program is complete and confirmed to function, the data from the
experimental subjects must be analyzed in more detail. Muscle, buffy coat and red blood cell
samples from the experimental subjects must be analyzed to calculate protein turnover rates.
Once we have a database of healthy protein turnover rates, we will design experiments with
subjects who have diseases so turnover rates may be compared between healthy and sick
conditions. Such a comparison could provide a turnover rate based biomarker or an improved
understanding of the disease state. These diseases include mitochondrial dysfunction or age
relating wasting of muscle tissue.
An area of exploration is the difference observed between the male and female subjects.
Previous studies have reported that males and females have significant differences in protein
turnover rates10. It will be an important test to see if we observe the same effect.
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5. Short-Term Calorie Restriction Elicits Nutrient-Specific Post-Transcriptional
Regulation of Proteostasis

5.1 Chapter Summary
Like the previous chapter, this work has not been published, though some of the mice
from these experiments were used for the papers presented in the chapters “DeuteRater: a Tool
for Quantifying Peptide Isotope Precision and Kinetic Proteomics” and “Mechanisms of in vivo
Ribosome Maintenance Change in Response to Nutrient Signals”. The goal of this work was to
combine kinetic proteomics with other methods to create a workflow that can solve biological
questions.
5.1.1 Authors in Order of Contribution
Bradley C. Naylor*, Richard Carson*, Monique Speirs, Nathan Keyes, Ryne Peters,
Brittany Johnson, Stephen Ames, Benjamin T. Bikman, Jonathan T. Hill, John C. Price
* These authors contributed equally to this work
5.1.2 Contributions of Major Authors
For this work, I led the mouse work on the high protein diet, the kinetic proteomic
analysis, and the quantitative proteomics analysis. My co-first author, Richard Carson, led the
mouse work on the low protein diet, the RNA-Seq work, and the combination of the datasets.
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5.2 Abstract
Biological aging seems to be primarily driven by a loss of protein homeostasis 1,2. For
over 100 years it has been known that dietary signals can change the rate of aging3,4. We, and
others, therefore have concluded that the rate of protein homeostasis loss can be slowed by
dietary interventions. Several very insightful investigations into protein homeostasis have
utilized luciferase or similar reporters as genetic reporters to identify important differences
between long lived and short lived animals1,2. Further insight into the regulation of protein
homeostasis would benefit from measuring individual synthesis and degradation rates for each
protein in the proteome systems wide measurement to identify how protein specific regulation of
these processes contributes to the maintenance or loss of protein homeostasis.

5.3 Introduction
Cells are not simple nor static. They constantly change in response to their needs and
various external stimuli. Healthy cells monitor and modify these changes with exquisitely fine
control. Loss of control is the basis for many of the untreatable diseases plaguing society today.
Control of protein quality and concentration in the cell is termed proteostasis. Synthesis, folding,
and degradation of each protein in the cell need to be controlled in order for protein homeostasis
to be maintained. Loss of proteostasis is the root cause of aging1,5-8, cancer9-11, and
neurodegeneration12-15.

Loss of proteostasis is often observed by dramatically changing protein

concentrations. Concentration control occurs through the careful balance of synthesis and
degradation. In fact, the classic model for change in protein concentration includes the rates of
synthesis and degradation (Equation 5-1).
𝑑𝑑[𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃]
𝑑𝑑𝑑𝑑

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 [𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚]
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

= 𝑘𝑘

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 [𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃]
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

− 𝑘𝑘
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− 𝑘𝑘

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 [𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣]
𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖

(5-1)

In terminally differentiated cells as found in the majority of human tissues we can assume
the kdivision is essentially zero. Which means that changes in concentration are due to the
difference in synthesis rate versus the degradation rate. Methods for measuring protein
concentration in vivo are well developed16,17 using mass spectrometry relative and absolute
concentrations can be measured for thousands of individual proteins in a biological sample.
Measuring concentration changes over time though is not sufficient to be able to know what is
happening with synthesis and degradation. For example, concentration may go up in a condition
but that increased concentration may be the result of an increase in protein synthesis or a
decrease in degradation rates.
The replacement (turnover) rates of each protein are also controlled by the individual
synthesis and degradation rates. We and others have recently developed methods to monitor
protein turnover rates for thousands of individual proteins in vivo18-22. Canonically, turnover can
be described as the average of synthesis and degradation rates (Equation 5-2)
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 (𝐷𝐷𝐷𝐷𝐷𝐷 −1 ) = (𝑘𝑘 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 ([𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚]) + 𝑘𝑘

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

([𝑃𝑃𝑃𝑃𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡]))/2

(5-2)

Although changes in turnover are indicative of changes in synthesis and degradation, it is

not known which component (synthesis or degradation has changed). For example, slowed
turnover could result from synthesis, degradation, or both slowing. The combination of change
in turnover and change in concentration is needed to identify whether synthesis or degradation is
primarily changed between control and experimental conditions for a given protein or group of
proteins.
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Figure 5-1 Experimental Workflow. Mice were fed experimental diets for 10 weeks and then labeled with
D2O. The mice were then sacrificed at various time-points throughout the following month. Liver was
taken and prepared for various analyses. Some had the RNA extracted for RNA-Seq, while the rest was
fractionated for Kinetic Proteomics or mixed with SILAC standard for Quantitative Proteomics
In order to analyze changes in proteostasis we used RNA-Seq, Quantitative Proteomics,
and Kinetic Proteomics, which measure mRNA quantity, protein quantity and protein turnover
rate respectively (Figure 5-1). With protein concentrations and turnover rates determined we
were able to determine how any measured protein was regulated (synthesis, degradation or both)
while the mRNA showed into where the regulation occurred and why.
To analyze changes in proteostasis we chose dietary restriction (DR) as a model. DR
involves feeding an organism reduced amounts of food, and extends lifespan substantially3,4.
Using DR as our test intervention offers two large advantages: First, DR has been studied for
decades, and has had multi-omics studies with quantitative and kinetic Proteomics performed
previously5,20, which provides a baseline for comparisons. Second, in those decades of study,
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several disruptions to DR have been found. Different genotypes and mutations can prevent DR
from prolonging life 23,24. Different dietary compositions and additives can disrupt DR 25,26. We
can analyze DR disruptions to determine if the disruption is affecting only specific pathways or
affecting the proteome in a more general way. By providing insight into what is disrupted, we
may identify mechanisms of DR’s beneficial effects. We chose to use diets with different
protein levels for this study due to the ease of performing the disruption. Previous work has
shown that high protein content in a diet can disrupt beneficial DR effects such as insulin
sensitivity26. Low protein (LP) and High protein (HP) chows were used and each diet had an ad
libitum (AL) and DR cohort.
We show that a high protein DR diet undoes the global decrease in protein turnover rates
and protein quantitation observed in canonical DR. We also show that this change is driven by
post-transcriptional control of proteins. Finally, we suggest a method of proteostatic control that
may be at work in DR. In the future, we will determine other biological pathways associated
with this change, and perform follow up experiments to confirm our observations.

5.4 Methods
5.4.1 Animal Handling
5.4.1.1 Mouse housing, genotype, and diet
Mouse diets, housing, and metabolic labeling were performed according to protocols
approved by the Institutional Animal Care and Use Committee of Brigham Young University.
Ten-week-old C57/Bl6 male mice were purchased from Charles River Laboratory. They were
stored in a pathogen free facility for the duration of the experiment. Mice were fed an AL diet
for one week after arrival to acclimate to the facility. Mice were then randomly divided into AL
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or DR groups. Mice were housed separately to ensure equal access to food. AL animals had
constant access to food, while DR animals were fed daily a pellet of 3g ± .1g in size (65% of
expected AL consumption). The HP diet was Harlan 8604 chow; the LP diet was NIH31 chow.
5.4.1.2 Metabolic Labeling
At 10 weeks, the mice were given an intraperitoneal bolus injection of sterile D2O saline
at 35 µL/g body weight. This injection brought the mice up to 5% Molar Percent Excess (MPE)
deuterium as previously described20. Mice were then provided drinking water containing 8%
MPE to maintain the 5% MPE in the animals’ body water.
5.4.1.3 Euthanasia and Sample Collection
Mice were anesthetized with CO2 and then euthanized by cardiac puncture. Mice were
then immediately dissected and all tissues except for blood were flash frozen on solid CO2 and
then stored at -80°C. Blood was stored on ice until it could be centrifuged at 800 x g for 10
minutes at 4°C. The centrifugation separated serum and red blood cells, which were stored in
separate containers at -80°C.
5.4.1.4 Mouse Weight Determination
Mice were weighed weekly on a laboratory scale. The scale was tared using a sterile
plastic bucket. The mouse was placed within the bucket and weighed. After weighing, mice
were placed back in their cages. Weighing was performed weekly during one of the daily
feedings of DR animals, in order to minimize distress to the animals.
5.4.1.5 Mitochondrial Respiration
Fresh liver tissue was quickly removed from exsanguinated mice and immediately placed
in ice-cold mitochondrial respiration buffer 05 (MiR: 0.5 mM EGTA, 10 mM KH2PO4, 3
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mM MgCl2-6 H2O, 60 mM K-lactobionate, 20 mM HEPES, 110 mM Sucrose, 1 mg/ml fatty acid
free BSA, pH 7.1) and trimmed of connective tissue. Tissue was gently separated and
homogenized under a surgical scope (Olympus, ST) to particles of around 1 mg. Homogenate
was then transferred to a tube with chilled MiR05 and 50 μg/ml saponin and rocked at 4 °C for
30 min, then washed in MiR05 at 4 °C for at least 15 min before use. High-resolution
O2 consumption was determined at 37 °C using the Oroboros O2K Oxygraph. Before addition of
sample into respiration chambers, a baseline oxygen consumption rate was determined. After
addition of sample, the chambers were hyperoxygenated to ∼350 nmol/ml. Following this,

respiration was determined as indicated. Lastly, residual oxygen consumption was measured by
adding antimycin A (2.5 μM) to block complex III action, effectively stopping any electron flow
and providing a baseline O2 consumption rate.
5.4.1.6 Differences between Cohorts
LP and HP cohorts were purchased and treated at different times due to logistical
concerns. The LP AL and LP DR cohorts had 9 mice each. The HP AL cohort had 19 mice and
the HP DR cohort had 20 mice. Due to the difference in cohort size, sacrifice times were
different. Two LP animals from each diet were sacrificed at 1 day, 3 days, 9 days and 27 days
after bolus D2O injection, with one animal from each group sacrificed without receiving a bolus
injection or any other D2O labeling. The HP mice had two animals sacrificed at 9 hours, 1 day, 2
days, 4 days, 8 days, 16 days, and 32 days post injection, with the 4, 8 and 32 day time-points
each having a third sacrifice and 2 mice per cohort sacrificed without deuterium injection. The
HP DR’s extra mouse was sacrificed with no bolus injection.
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5.4.2 Kinetic Proteomic Analysis
5.4.2.1 Measurement of MPE
For animals in LP cohorts, serum was distilled to measure MPE as described in Chapter
“Mechanisms of in vivo Ribosome Maintenance Change in Response to Nutrient Signals”. For
animals in HP cohorts the serum and 100 mg of liver homogenate (made using MP Biomedicals
FastPrep-24 bead beater) were used. These samples were distilled at 90°C overnight and the
distillate collected. In both LP and HP, the following steps were identical. The distillate was
diluted 1:300 in ddH2O, and MPE of deuterium was directly measured against a D2O standard
curve using a cavity ring-down water isotope analyzer (Los Gatos Research [LGR], Los Gatos,
CA, USA) according to the published method 27.
5.4.2.2 Trypsin Digestion
Liver tissue from each animal was placed in Ammonium Bicarbonate (ABC) solution (25
mM, pH 8.5) along with protease inhibitor cocktail (Sigma) and was homogenized using a MP
Biomedicals FastPrep-24 bead homogenizer at 6 m/s for 60 seconds. Volumes were calculated
to give approximately 10 mg/mL protein. Protein concentration was measured using a
bicinchoninic acid (BCA) protein assay (Thermo Fisher). 300-500 µg of protein were placed on
30 kDa centrifugal filters (VWR). 100 µL of guanidine (6 M, 100 mM Tris-HCl pH 8.5) was
added to each sample and centrifuged at 14,000g for 15 minutes. Another wash with guanidine
(same volume and centrifuge settings) was performed. Flow-through was discarded. 100 µL of
guanidine was added to the filters, and the solution was brought to 10 mM dithiothreitol. The
filters with sample were placed in a sand bath at 60 °C for 60 minutes. After 5 minutes of
cooling, the samples were brought to 20 mM iodacetamide. The samples were then incubated in
the dark for 60 minutes. Afterwards, the samples were centrifuged at 14,000g for 15 minutes.
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200 µL ABC was added to the filters, which were spun at 14,000g for 15 minutes. After a
second ABC wash (same volume and centrifuge settings), ABC was added to the filters to a final
volume of 300 µL. Collection vials were emptied and cleaned. Pierce MS-Grade Trypsin was
added to a 1:50 (w:w) in each sample, which were incubated at 37°C overnight. The next
morning, samples were centrifuged at 14,000 g for 30 minutes. 100 µL of ABC was added to the
filters and they were centrifuged again for 30 minutes at 14,000 g. Filters were discarded and the
filtrate was dried using a Speedvac (Sorval) vacuum centrifuge. The dried samples were stored
at 4°C until use.
5.4.2.3 HPLC Fractionation
Samples were re-suspended in 10 mM ammonium formate (LC-MS grade pH 9.5).
Samples were fractionated using high pH C18 High Performance Liquid Chromatography
(HPLC), which is orthogonal to low pH C18 chromatography used in “LC-MS Data Acquisition”
allowing for improved protein coverage 28. Fractionation was performed using the 1260 HPLC
Infinity (Agilent) and the Gemini 50 x 2.00 mm C18 column with 3µm beads and 110 angstrom
pore size. Peptides were eluted using a 10 mM ammonium formate (pH 9.5) H2O/acetonitrile
gradient from 3% B to 60% B over 40 minutes flowing at 1 mL/min. Buffer A was 97% H2O,
3% acetonitrile, 10mM ammonium formate pH 9.5. Buffer B was 10% H2O, 90% acetonitrile,
10mM ammonium formate pH 9.5. 1 mL fractions were collected. 1 mL fractions were pooled
into 8 fractions by pooling every 8th fraction. For example, fractions 1, 9, 17, and 25 were
pooled into one fraction. Pooling was performed in this manner to spread out high abundance
peptides to different fractions. By spreading out peptides in this way, more coverage can be
obtained within the dynamic range of the mass spectrometer. It also ensured varied
hydrophobicity of peptides within each sample allowing the chromatography for the LC-MS to
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be most effective. Pooled fractions were dried with a SpeedVac vacuum centrifuge (Sorval) then
suspended in 200 µL of 80% acetonitrile and decanted into a mass spectrometry vial. Samples
were again dried with a SpeedVac vacuum centrifuge (Sorval) and suspended in 40 µL of 3%
acetonitrile 0.1% formic acid (all LC-MS grade) for LC-MS analysis.
5.4.2.4 LC-MS Data Acquisition
As described previously, protein identification and kinetic acquisition were performed on
an Agilent 6530 Q-ToF mass spectrometer coupled to a capillary nanoflow Agilent 1260 HPLC
using the chipcube nano-spray source20,21. Peptides were eluted from an Agilent C18 Polaris
chip at 300 nL/min using an H2O-acetonitrile gradient acidified to pH 4 by Pierce LC-MS grade
formic acid. Buffer A was 3% acetonitrile, 0.1% formic acid. Buffer B was 97% acetonitrile,
0.1% formic acid. The elution gradient was as follows: 0 minutes, 100% A; 0.1 minutes, 95% A;
27 minutes, 40% A; followed by high percentage B column washing and low percentage B reequilibration. The Agilent 6530 Q-ToF mass spectrometer was run in 2 Ghz high dynamic range
mode. Protein identification runs were performed in MS/MS mode using collision-induced
dissociation with nitrogen gas. MS and MS/MS data were collected at a maximum rate of 4
spectra/second with CID fragmentation on the top 10 most abundant precursors. Dynamic
exclusion was set to 0.2 minutes. Kinetic acquisitions were performed in MS only mode and
collected at 1 spectra/second. MS only mode increases signal intensity, improves signal-tonoise, and gives more scan points per elution chromatogram, greatly enhancing isotopomer
analysis accuracy. Data were also collected on an Orbitrap Fusion-Lumos mass spectrometer.
Samples were resuspended in 0.1% formic Acid (Pierce LC-MS grade) in H2O (Optima grade
Thermo Fischer). Samples were analyzed with a Thermo Lumos Tribrid (Orbitrap). Tryptic
peptides were separated using a reverse phase C18 column (Acclaim PepMap™ 100) and a
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Thermo Easy-Spray source. Mobile phase for the liquid chromatography was 0.1% formic acid
in H2O (Buffer A) and 0.1% formic acid in 80% acetonitrile (Optima grade Thermo Fischer)
with 20% H2O (Buffer B) on an Easy-nLC 1200 HPLC system. Samples were eluted using a
gradient of 5% B to 22% B over 85 minutes, 22% to 32% B over 15 minutes, with a wash of
32% to 95% B over 10 minutes, which was held at 95% B for 10 minutes. Sample loading and
equilibration were performed using the HPLC’s built-in methods. MS only runs were performed
using 2400 V in the ion source, 60000 resolution with a scan range of 375-1700 m/z, 30% RF
Lens, Quadrupole Isolation, 8 *10^5 AGC Target and a maximum injection time of 50 ms.
MS/MS scans were performed using the same settings as used for MS only scans with 3 seconds
allowed per MS/MS after each MS scan. The following filters were used: peptide monoisotopic
peak determination, an intensity threshold of 5*10^3, fragmentation limited to charge states +2
to +6, with an error tolerance of 10 ppm high and low, and isotopes excluded. Dynamic
exclusion allowed fragmentation of any peak once every 60 seconds. The fragmentation scan
used an isolation window of 1.6 m/z, CID fragmentation with an energy of 30%, detection in the
linear ion trap in Rapid Scan mode with a AGC target of 1*10^4, a maximum injection time of
35 milliseconds and used the “Inject Ions for All Available Parallelizable Time” option.
5.4.2.5 Protein Identification
Peak lists obtained from MS/MS spectra were identified using Mascot version 2.2.04,
OMSSA version 2.1.9, X!Tandem version X! Tandem Sledgehammer (2013.09.01.1), MS-GF+
version Beta (v10282), Comet version 2016.01 rev. 2 and MyriMatch version 2.2.140. The
search was conducted using SearchGUI version 3.2.729.
Protein identification was conducted against a concatenated target/decoy version of the
Mus musculus complement of the UniProtKB (Created September 2016 , 16806 (target)
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sequences). The decoy sequences were created by reversing the target sequences in SearchGUI.
The identification settings were as follows: Trypsin, Specific, with a maximum of 2 missed
cleavages 10.0 ppm as MS1 and 0.5 Da as MS2 tolerances; fixed modifications:
Carbamidomethylation of C (+57.021464 Da), variable modifications: Oxidation of M
(+15.994915 Da), Pyrolidone from Q (--17.026549 Da), Acetylation of protein N-term
(+42.010565 Da), Pyrolidone from E (--18.010565 Da), Pyrolidone from carbamidomethylated C
(--17.026549 Da), fixed modifications during refinement procedure: Carbamidomethylation of C
(+57.021464 Da).
Peptides and proteins were inferred from the spectrum identification results using
PeptideShaker version 1.15.130. Peptide Spectrum Matches (PSMs), peptides and proteins were
validated at a 1.0% False Discovery Rate (FDR) estimated using the decoy hit distribution. All
validation thresholds are listed in the Certificate of Analysis available in the supplementary
information. Post-translational modification localizations were scored using the D-score and the
phosphoRS score with a threshold of 95.0 as implemented in the compomics-utilities package. A
phosphoRS score above was considered as a confident localization.
After protein identification, identification files and the MS-only mass spectrometry data
were analyzed with the DeuteRater software package 18. DeuteRater provided the protein
turnover rates used for later analyses.
5.4.2.6 Homology Analysis
Due to sample fractionation and biological variability, some peptide sequences were
assigned to different homologous proteins in different experimental groups. To address this, all
identifications for every sequence within kinetic proteomics data sets were identified.
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Homologous sequences had the accession numbers combined to indicate uncertainty in the
identification. DeuteRater analysis was then redone to create homology corrected rates.
5.4.2.7 Filtering Data
Kinetic data required filtration to remove data with extreme outliers or other issues. The
kinetic proteomics data comes from a curve fit of relevant data, so all curves with an R2 less than
0.5, or with 95% confidence interval/ rate value less than 0.2 were removed from further
analysis. The confidence interval was divided by the turnover rate to normalize error to the
measured value.
5.4.3 Quantitative Analysis
5.4.3.1 Homogenization, Trypsin Digest, and HPLC fractionation
A mouse liver labeled according to a Stable Isotope Labeling by Amino Acids in
Mammals (SILAM) (Lys 6C13, Cambridge Isotopes) was purchased and homogenized as
described in the “Trypsin Digestion” section above. We mixed 150 µg of protein from the
SILAM homogenate with 150 µg protein from the sample homogenate. We used 3 replicates
from each dietary group. Due to isotopic shifts caused by D2O labeling creating difficulties in
peptide identification, only animals within one day of intraperitoneal injection, or those that
received no injection, were used for this experiment. The mixtures of SILAM and sample
homogenates were prepared identically to those described within the “Kinetic Proteomic
Analysis” section until mass spectrometry analysis.
5.4.3.2 Mass Spectrometry Analysis
Samples were re-suspended to 1 µg/µL in .1 % formic acid. Samples were analyzed on a
Thermo Lumos Tribrid instrument paired with a Thermo Easy-nLC 1200 HPLC. Solvent A was
.1% formic acid 100% water, Solvent B was .1% formic acid, 80% ACN 20% water. All
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solvents were LC-MS grade. Gradient was as follows: 0-45 minutes was 5-45 % Buffer B, 45-50
minutes 45-100 % Buffer B, 50-60 minutes 100 % Buffer B. The MS scans were collected at
60,000 Resolution, with 20 MS/MS scans between MS scans. MS/MS fragmentation was done
with a 1.6 m/z isolation window, CID fragmentation with 28% fragmentation energy. Fragment
ions were measured in the Linear Ion Trap with the “Normal” resolution setting.
5.4.3.3 Data Analysis
Data from the mass spectrometry analysis was analyzed using the MaxQuant software
package31. All data was analyzed at the same time, with each dietary group analyzed as a single
experimental group. Constant modifications were carbamidomethylation for cysteine. Variable
modifications allowed were oxidation of methionine and acetylation of the N-terminus. The
identification database was the same as that used for the kinetic analysis. Lys6 was added as a
heavy label, all other settings were left at default. Unlabeled divided by labeled signal intensities
were determined and used to determine amounts of peptide in the sample relative to the SILAM
standard. The relative peptide abundances could then be compared between samples.
5.4.4 RNA-Seq
We used the Direct-zol RNA MiniPrep Plus kit from Zymo Research to extract RNA
from liver tissue of all animals in this study. Briefly, 10-20 mg of frozen liver tissue from each
mouse was processed using a Trizol extraction and the resulting RNA frozen at -80°C. Since we
wished to identify changes in the transcriptome that resulted only from dietary differences, RNA
from three different mice in the same dietary cohort (but sacrificed at different times) were
pooled to form a single sample for RNA-Seq, thus masking any differences resulting from
temporal variations. There were three pools per dietary cohort, containing RNA from three mice
each. Sample volumes were adjusted to obtain a concentration of 4µg total RNA in 50 µL of
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RNase-free water, and submitted to the BYU Sequencing Center. The BYU Sequencing Center
constructed cDNA libraries after a poly-A pull-down to enrich for mRNA, and then sequenced
them using an Illumina HiSeq 2500 sequencing platform. RNA-Seq bam files were analyzed in
R using the DESeq2 package in Bioconductor 3.3 from Bioconductor.org32, downloaded October
20, 2016.
5.4.5 Multi-omics Data Analysis
5.4.5.1 Differential Expression Determination
Turnover rate data, quantitative MS data, and RNA-Seq data were first filtered in this
fashion: Protein/Gene IDs were matched between all dietary groups. Any proteins/gene IDs that
were not common to all four diets were excluded from further analysis. 95% confidence
intervals were then calculated for each measurement based on data output from DeuteRater,
MaxQuant, and DESeq2, for protein turnover data, quantitative data, and RNA-Seq data
respectively. Using R scripts, proteins/genes that were significantly different between diets were
identified by analyzing overlap between mean values and confidence intervals: in order to be
considered different between diets, the mean value of one diet had to lie outside of the
confidence interval of the other compared diet, and vice-versa. Any that failed this test were
labeled as matching, and assigned a value of zero difference. Permutation tests to guard against
false discovery are in process. For comparison between kinetic, quantitative, and RNA-Seq data,
any protein that did not occur in all three sets was excluded from analysis. For LP and HP diet
comparisons, proteins were excluded if they were not observed in both dietary data sets.
Graphical output of the data was performed using JMP12, Microsoft Excel, and RStudio (version
0.99.903).
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5.4.5.2 Gene Ontology Analysis
Ontology groupings were determined using DAVID 33,34; proteins/genes were separated
into three general categories: “up,” “equal,” and “down” according to whether the ratio of DR to
AL was greater than one, equal to one, and less than one, respectively. These categories were
determined using the non-overlapping confidence interval test described in the “Differential
Expression Determination” section. Ensembl IDs from RNA-Seq data were translated to
UniProt accession numbers prior to ontology analysis. Gene ontology output from DAVID used
background groups comprised of all categories combined together. Ontology groups with
Benjamini coefficients less than or equal to 0.05 were retained for analysis; all others were
disregarded.
5.4.5.3 RNA-Motif Analysis
RNA motif analysis was performed using the HOMER motif analysis tool35 in order to
detect translational preference due to RNA sequence motifs in the mRNA. Output from
HOMER was processed using in-house R scripts.
5.5 Results
5.5.1 High Protein Diet Elicits Canonical Phenotypes
Mice were weighed throughout the experiment to ensure the health of the animals, and
to analyze differences in the diets (Figure 5-2 Panel A). We also analyzed the effect of different
diets on mitochondrial respiration immediately following euthanasia (Figure 5-2 Panel B-C).
The results of both of these tests show that DR is different from AL in phenotypic ways,
decreasing in both weight and mitochondrial oxygen consumption. HP-DR evidences more
severe weight loss relative to its control than LP-DR, even though the AL groups are very
similar. This indicates a disruption of some part of the DR phenotype caused by higher dietary
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protein. However, the effect of different amounts of protein in DR on a cellular level required
more in-depth analysis to determine.

Figure 5-2 Comparison of Weight and Mitochondrial Respiration. Panel A is a comparison of mouse
weights over the course of the experiment. Each animals’ weight was normalized to its weight at the
start of the experiment. Each point on the graph represents an average of the normalized data at that
time-point. The AL dietary groups are nearly identical. In both DR groups, weight decreases
immediately and eventually increases, but the relative decrease is far larger in HP-DR than LP-DR.
Panel B represents the mitochondrial use of oxygen in various conditions. Leak is the mitochondria
at rest with oxygen, ATP is the addition of ADP and oxygen to show function of the Electron
Transport Chain other than complex 2, and the Succinate effect shows complex 2 added to the rest of
the Electron Transport Chain. The AL seems to use more oxygen than DR in both diets. HP-DR
seems to use less oxygen compared to its AL than LP in all cases. Panel C shows the relative
efficiency of the ATP effect and the Succinate effect compared to mitochondrial leak. The data
suggests that the HP diets might have a slight increase in efficiency compared to LP, but the error is
too high to be sure.
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5.5.2 Protein make-up of diet affects DR globally
A key observation in previous studies of DR has been that DR slows average protein
turnover rates and decreases the average protein quantity5,20. Our study replicates these previous
observations in our low protein groups (Figure 5-3 A and C). In the high protein diet, DR does
not have this effect, resulting in minimal change to global protein turnover rates between DR and
its AL control (Figure 5-3, B and D). This is important to the protein homeostasis hypothesis of
DR. This hypothesis states that the DR benefit to lifespan is the result of more time being spent

Figure 5-3 Rate and Turnover Comparison. Comparison of Protein turnover rates (A-B) and

Quantitation (C-D). If samples are identical, the fit line should have an approximate slope of 1, which
is the case in High Protein Quantitation (Panel D, slope = .9845), and is a not far off in HP Turnover
rates (Panel B, slope = .938). For LP the slopes are far lower than in their HP counterparts(Turnover:
Panel A slope =.7788, Panel C slope = .8699). This indicates that the LP DR is far more different from
its AL than the HP DR is from its AL.

on protein translation20. The hypothesis is that the decreased demand on the protein translation
machinery allows fewer mistakes and more time for the quality control machinery to work. This
change in turnover rate may be responsible for the phenotypic changes observed by other groups

131

26

but how the turnover rate and phenotypic changes influence each other has not yet been

determined. Our previous work20 and the literature36,37 have identified the strong connection
between reduced mTOR signaling and the DR effect. Conversely, it has been established that
mTOR activity is directly connected to amino acid and in particular leucine concentration38,39.
Therefore, the effect of the high protein diet may be, in part, to activation mTOR in spite of the
reduced calorie diet. This would have a direct impact on global synthesis and degradation rates.

Figure 5-4 Comparison of mRNA amounts. A comparison of DR mRNA (y-axis) counts to AL mRNA

counts (x-axis) in both LP (Panel A) and HP (Panel B) diets. A slope of 1 would indicate no change
between the diets. Since the slopes are very close to 1, it can be seen that there are no major differences
within the diets in terms of mRNA amounts.

5.5.3 The Proteome is Controlled Post-Transcriptionally during DR
The RNA-Seq data showed remarkably little change regardless of dietary changes
(Figure 5-4A). This was particularly interesting considering there were statistically significant
changes in quantitative and kinetic measurements both for individual proteins and globally in the
LP diet (Figure 5-3 A and C). This indicates that the observed changes to the proteome, and
presumably the phenotypic benefits, of LP DR are regulated post-transcriptionally.
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In an effort to explain how this post transcriptional regulation occurs, we analyzed the
RNA-Seq data for evidence that changes in protein concentration or kinetics are correlated with
micro-RNA motifs, transcriptional activating factors, or other RNA motifs that are known to
regulate mRNA longevity and translation. These tests found no evidence of gene-specific
control at this level. This indicates that the post-transcriptional control is unlikely to be driven
by RNA sequence based regulation. Using the combination of turnover and concentration
changes for each protein, we can identify the primary control mechanism for the mechanism of
post-transcriptional regulation that is active during protein translation or degradation.

Figure 5-5 Ontology Analysis of HP vs LP Diets. Venn diagram of the differences observed when LP and

HP diets were compared. Groupings were determined by the process described in “Gene Ontology
Analysis” in the methods section. Comparison is between DR and AL, so if an ontological group shows a
red Up arrow under the RNA header, there is more mRNA from that group in DR than AL and vice versa.
This figure demonstrates that there are clear differences between diets affecting important cellular
pathways
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5.5.4 Ontology Groupings
After the global protein trends were determined, we grouped proteins whose kinetics or
concentrations responded in similar ways from the various diets and tested whether there was a
statistically significant change in the concentration or kinetics for the proteins as a group.
Significance of the change for the group was assessed by comparing to the background of all
proteins observed. The results of the ontology analysis are shown in Figure 5-5, with all results
(up, down or unchanged) being a comparison of DR relative to AL. Our ontology analysis
demonstrated that some large functional categories respond similarly to DR regardless of dietary
protein, such as mitochondria and the ribosome. It should also be noted that the LP analysis
showed more ontologies and more of those detected were changed compared to AL. This fits
with the global shifts in protein turnover rate and quantitation observed in LP diets but not in HP
diets.
5.5.5 Regulation can be Determined through Multi-Omics
By using our multi-omics approach, we have determined that changes in concentration
and turnover of many proteins throughout the proteome during DR with added dietary protein are
controlled post-transcriptionally. Although mRNA concentrations were unchanged we observed
that many proteins experienced a significant change in concentration. The turnover rate decrease
for the majority of observed proteins is consistent with previous literature20, and when compared
against the change in concentration we can identify whether synthesis or degradation is primarily
regulated under these conditions.
In comparing LP to HP diets, we have determined that the HP disruption of LP DR
extends to global proteome maintenance, expanding beyond the specific pathways previously
observed26. We have determined that the large decreases in protein turnover and quantity we and
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others8,20 have observed in LP DR compared to its AL control are almost entirely lost during HP
DR.
5.5.6 Identification of Possible Regulatory Mechanism
Our ontological analysis (Figure 5-5) indicated that one of the functional groups showing
the greatest variation between HP and LP dietary restriction diets was translational
machinery. We hypothesized that a large-scale regulatory change in a protein functional group
involved in translation could be responsible for the overall slowing of protein synthesis observed
in LP dietary restriction. The proteins involved in translational machinery were subdivided
based on the general roles they fulfill during protein synthesis (e.g. ternary complex formation,
ribosomal structure, tRNA charging), and analyzed for differences between HP and LP dietary
restriction diets. Of all of these subgroups, the most striking differences were found in the tRNA
synthetases. While the RNA-Seq data for these enzymes was unchanged, similar to the overall
RNA-Seq trends, the concentration for many of the tRNA synthetases was significantly lower in
LP-DR versus HP-DR diets (Figure 5-6). When we compared the turnover rates, we observed
that the majority of the synthetases were being turned over at a faster rate in LP diets, suggesting
that these synthetases were undergoing higher degradation rates. However, about one-third of
the synthetases were being turned over at a slower rate in LP diets, indicating decreased
synthesis.
It has been observed in previous studies that tight regulatory control over protein
translation can be enacted through control of the amino acid-charged tRNA pool40-42. Stimuli
such as cellular stress43 and lack of nutrition44can cause significant changes in the amount and
species of tRNA that are produced and charged with amino acids45. By manipulating the amount
of specific amino-acyl tRNAs, the cell could bias protein production to favor mRNA’s
135

Figure 5-6 Analysis of tRNA Synthetases: When analyzing proteins involved in translation to find a posttranscriptional control mechanism, we observed that concentrations of 18 out of 20 tRNA syntethases
were significantly lower in LP-DR, but not HP-DR which could explain the slower general protein
translation rate in LP. The changes in turnover rates of the synthetases indicates differential regulation
of the individual enzyme concentrations.

containing specific codons, allowing the cell to quickly adjust to changing environmental
conditions45,46. However, although mechanisms in E. Coli and yeast40,41 have been studied, the
methods the eukaryotic cells could use to cause such tRNA biases are not well understood.
Our data suggest that liver cells may do this is by fine-tuned regulation of tRNA
synthetase activity. The quantity of a particular tRNA synthetase is expected to have a direct
effect on the overall production rate of its amino-acyl tRNA; if the quantity of the charging
enzyme goes down, we would expect the concentration of the corresponding amino-acyl tRNA
to decrease as well. This would have a wide-scale dampening effect on protein synthesis both
through reduction of raw material provided to the ribosome, as well as through the Gcn2
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regulatory pathway, which responds to increasing amounts of uncharged cytosolic tRNA41
(Figure 5-7).
The change in tRNA synthetase regulation could be tied to changes in amino acid
availability, which could logically cause decreased cytosolic concentration of tRNA synthetases
through regulatory feedback mechanisms. This could be tested by measuring free amino acid
and tRNA concentrations in the tissue. Also, direct measurement of the percentage of charged
amino-acyl tRNA for all amino acids would test for a tRNA pool perturbation occurring as a
result of differential dietary protein amounts. The results of these experiments are expected to
confirm whether alterations to the tRNA pool constitute a major cellular mechanism resulting in
the phenotypic benefits observed with DR.

5.6 Discussion
Using quantitative and kinetic proteomics, we have shown that we can simultaneously
monitor regulation of synthesis and degradation of large numbers of individual proteins in vivo.
This is particularly important in studying dietary restriction (DR) where RNA-Seq showed that
the mRNA concentrations were remarkably unchanged by DR. These results suggest that there
is significant post-transcriptional regulation due to dietary changes for most of the proteome.
This, along with data on weight and mitochondrial respiration, suggests a major change
disruption of DR based on dietary protein level, as well as suggesting a possible mechanism for
the disruption. The HP DR animals may be attempting to maintain protein levels and turnover
rates with less energy to do so. Maintaining high protein turnover and concentration requires
energy and raw materials. Draining resources to try to maintain an AL proteome with DR
resource levels could result in animals using more of their body weight as energy. Furthermore,
this changed energy response could also affect the mitochondria due to its role in metabolism.
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Lending credence to this hypothesis, both the respiration data and ontology analysis suggest that
mitochondria were remodeled as part of both DR phenotypes. If the dietary protein creates strain
on the mitochondria and the organism more generally, the changed energy requirements could
undo the benefits of DR as observed by Solon-Biet, which includes reducing the lifespan back
towards AL lifespan26,47. Another hypothesis is that DR is beneficial because the lowered
protein turnover permits greater quality control of the synthesized proteins 48. If the dietary
protein encourages increased protein turnover rates globally, the hypothesis predicts an AL-like
phenotype should be observed. Differentiating between these hypotheses, and identifying
differences in signaling between the LP DR and HP DR diets requires further investigation.
A critical clue into the investigation of dietary signalling is the RNA-Seq data. Neither
DR treatment shows a significant change from AL, nor does protein level change the correlation
between AL and DR. This suggests that whatever DR or dietary protein are signaling to the cell,
the signal is affecting the proteome after RNA is transcribed. The logical control points would
be the ribosome, which synthesizes all proteins, or the various protein degradation pathways.
Our primary hypothesis currently is the global shift in homeostasis that occurs during DR
is orchestrated in large part by control of the tRNA synthetase enzymes. A reduction in the
charging of tRNA would cause global shifts in protein synthesis by the ribosome (Figure 5-7).
Interestingly, the relative charging percentage of tRNA is carefully monitored and is tied to the
activity of the GCN2 kinase. When uncharged tRNAs bind to GCN2 it acts immediately to
repress translation by phosphorylation of eIF-2α at serine 51 within 15 min of amino acid
deprivation49. Therefore, the regulation of the tRNA synthetase enzymes may be a longer-term
result of the initial GCN2 signaling. Data suggests individual regulatory mechanisms for
different tRNA synthetases, but we have not analyzed the individual mechanisms at this time. In
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the future, we will examine the amount of tRNA in the cells. We will also attempt to observe
quantity and phosphorylation state of various control proteins through more targeted mass
spectrometry or immuno-affinity assays.

Figure 5-7 Model of tRNA in DR. Known model of tRNA synthetases control of protein translation.
Our contribution to the model is the dietary control of the tRNA synthetases.

5.7 Future Directions
Post-transcriptional control of the proteome in DR has been established, and dietary
protein has been shown to undo the kinetic and quantitative changes traditionally associated with
DR. We have evidence that the tRNA synthetase enzymes are a potential pathway for control of
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proteostasis due to dietary signaling. We are in the process of measuring tRNA levels and
charging to determine if differences in tRNA synthetase turnover and concentration are
responsible, at least in part, for the proteostatic regulation in LP-DR that is undone by high
dietary protein.
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6. Conclusions

Kinetic proteomics is an emerging field with great potential. Currently the need for
specialized analysis tools hinders broad use of the technique. I have led the development of tools
that both advance the calculations and are user friendly. By providing these tools, my team has
helped researchers unfamiliar with kinetic proteomics enter the field without needing to invest
months determining calculations and creating software tools, or needing to collaborate with one
of the few labs created the necessary calculation software in house. I have also led the group
improving our DeuteRater tool to work on the more complicated calculations needed to perform
kinetic proteomics in human subjects. By improving on both our own and existing tools, we
have the potential to extend human kinetic proteomics beyond one or two expert groups, and
make the technique available to all scientists.
I have also contributed to our knowledge of biology by using kinetic proteomics.
Working closely with other graduate students in the Price lab, I have been instrumental in
proving ribosomal protein exchange in eukaryotes, and so a possible method of ribosomal
maintenance. Not only is ribosomal maintenance critical to normal functioning of the cell, but
ribosomal maintenance may be responsible for dietary restriction’s (DR) beneficial effects on
longevity observed in mice. Finally, I worked closely other graduate students to determine
global regulation of the proteome in normal DR and the disrupted state caused by adding dietary
protein to DR. While work is still necessary to confirm our findings, it is possible that this study
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will shed needed light on the mechanism of DR in laboratory animals. Hopefully, our findings
can be translated into further discoveries in humans.
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7. Future Directions

The main future directions for this work are preparing DeuteRater-H for distribution, and
confirming the tRNA effect observed between High Protein and Low Protein DR. These
changes have been elaborated on in their respective chapters.
Other future directions include analyzing the ribosome in other conditions. A ribosomal
disease or a different time in the lifespan of a mouse would provide insight into how different
damage conditions affect ribosomal maintenance. A similar effort could be performed with DR,
examining how ribosomal maintenance changes in conditions that cause DR-like effects or are
immune to DR, such as different dietary conditions or different genotypes. Examining turnover
in these models could determine if improved ribosomal maintenance is specific to DR, or is
important to all metabolic lifespan extension mechanisms. It would also be useful to determine
ribosomal turnover in humans to see if the observations in mice translates to humans as well.
Finally, in DeuteRater, a direction we have not explored is improving higher resolutions
in the Orbitrap. When using the highest resolution settings on the Orbitrap, both abundance and
neutromer spacing decreased significantly in precision, accuracy, and number of proteins
observed. My hypothesis is that most of the problems at high resolution are caused by higher
resolution scans requiring more time. Instrument run time was identical for all instrument
conditions, which likely resulted in fewer scans to average together in data analysis. This lack of
data points results in worse signal to noise compared to other resolutions with more scans per
analysis run. If that is the case, lengthening the time of the experimental gradient proportionally

147

to the scan time should correct the issue, and should theoretically drastically improve neutromer
spacing metrics due to the increased resolution.
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